var title_f27_36_28224="Reasons for ART";
var content_f27_36_28224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Diagnoses among couples who had ART cycles using fresh nondonor eggs or embryos,* 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 414px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The above figure shows the infertility diagnoses reported among couples who had an ART procedure using fresh nondonor eggs or embryos in 2006. Diagnoses range from one infertility factor in one partner to multiple factors in either one or both partners. However, diagnostic procedures may vary from one clinic to another, so the categorization may also vary.",
"    <br>",
"     <strong>",
"      Tubal factor",
"     </strong>",
"     means that the woman's fallopian tubes are blocked or damaged, making it difficult for the egg to be fertilized or for an embryo to travel to the uterus.",
"     <br>",
"      <strong>",
"       Ovulatory dysfunction",
"      </strong>",
"      means that the ovaries are not producing eggs normally. Such dysfunctions include polycystic ovary syndrome and multiple ovarian cysts.",
"      <br>",
"       <strong>",
"        Diminished ovarian reserve",
"       </strong>",
"       means that the ability of the ovary to produce eggs is reduced. Reasons include congenital, medical, or surgical causes or advanced age.",
"       <br>",
"        <strong>",
"         Endometriosis",
"        </strong>",
"        involves the presence of tissue similar to the uterine lining in abnormal locations. This condition can affect both fertilization of the egg and embryo implantation.",
"        <br>",
"         <strong>",
"          Uterine factor",
"         </strong>",
"         means a structural or functional disorder of the uterus that results in reduced fertility.",
"         <br>",
"          <strong>",
"           Male factor",
"          </strong>",
"          refers to a low sperm count or problems with sperm function that make it difficult for a sperm to fertilize an egg under normal conditions.",
"          <br>",
"           <strong>",
"            Other causes",
"           </strong>",
"           of infertility include immunological problems, chromosomal abnormalities, cancer chemotherapy, and serious illnesses.",
"           <br>",
"            <strong>",
"             Unexplained cause",
"            </strong>",
"            means that no cause of infertility was found in either the woman or the man.",
"            <br>",
"             <strong>",
"              Multiple factors, female only,",
"             </strong>",
"             means that more than one female cause was diagnosed.",
"             <br>",
"              <strong>",
"               Multiple factors, female and male,",
"              </strong>",
"              means that one or more female causes and male factor infertility were diagnosed.",
"              <div class=\"footnotes\">",
"               %: percent.",
"               <br>",
"                * Total does not equal 100 percent due to rounding.",
"               </br>",
"              </div>",
"              <div class=\"reference\">",
"               Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"              </div>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28224=[""].join("\n");
var outline_f27_36_28224=null;
var title_f27_36_28225="EP study interpolated JPB";
var content_f27_36_28225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrophysiology (EP) study showing surface and intracardiac electrocardiograms of an interpolated junctional premature beat (JPB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous surface ECG leads I, II, V1 and intracardiac leads recorded from the high right atrium (HRA), distal (HBEd) and proximal (HBEp) His bundle, and the coronary sinus (CS) show an interpolated junctional premature beat (JPB, red asterisk). The first two beats originate in the sinus node with an initial atrial depolarization (A) followed by conduction through the His bundle (H) to the ventricle (V). There is no A deflection prior to the JPB; only a His deflection (H') followed by ventricular activation (V') are evident. After the JPB there is an on-time atrial impulse (arrow) that is conducted through the atrioventricular node with a long AH interval (AH').",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28225=[""].join("\n");
var outline_f27_36_28225=null;
var title_f27_36_28226="Collimaters comp a";
var content_f27_36_28226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56908%7EONC%2F68580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56908%7EONC%2F68580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schema of collimator and compensators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By passing each beam through an aperture shaped to correspond to the cross-sectional area of the lesion in the beam's bird's eye view, the cross-section of each proton beam is conformed to the corresponding silhouette of the lesion (collimation). By interposing specific materials in the beam's path, energy attenuation is achieved to account for the effects of sloping skin surfaces and tissue non-homogeneities (compensation).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Schema of collimator and compensators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A customized collimator/compensator used in proton radiosurgery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clark C Chen, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28226=[""].join("\n");
var outline_f27_36_28226=null;
var title_f27_36_28227="Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Drug information";
var content_f27_36_28227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/59/6067?source=see_link\">",
"    see \"Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13734606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DRAXIMAGE&reg; DTPA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13734607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13736154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Kidney imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 3-5 mCi (111-185 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      GFR estimation:",
"     </b>",
"     I.V. (based on 70 kg patient): 3-5 mCi (111-185 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal perfusion assessment:",
"     </b>",
"     I.V. (based on 70 kg patient): 10-20 mCi (370-740 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Brain imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 10-20 mCi (370-740 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Aerosol ventilation scintigraphy (unlabeled use):",
"     </b>",
"     Inhalation: 25-35 mCi (900-1300 MBq) (Society of Nuclear Medicine, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CSF leak detection (unlabeled use):",
"     </b>",
"     Intrathecal: Subarachnoid injection: 1-3 mCi (37-11 MBq) (Kowalsky, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystography, retrograde (unlabeled use):",
"     </b>",
"     Intracatheter (urethral): 0.5-1 mCi (18.5-37 MBq) (ACR, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystography, anterograde (unlabeled use):",
"     </b>",
"     I.V.: 10-15 mCi (ACR, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Evaluation of renovascular hypertension (unlabeled use):",
"     </b>",
"     I.V.: 1-10 mCi (185-370 MBq) (Taylor, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13736265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Brain imaging (unlabeled use):",
"     </b>",
"     I.V.: 0.2 mCi/kg (7.4 MBq/kg); minimum: 10 mCi (370 MBq); maximum: 20 mCi (740 MBq) (Donohoe, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diuretic renography (unlabeled use):",
"     </b>",
"     I.V.: 0.1 mCi/kg (3.7 MBq/kg); minimum: 1 mCi (37 MBq) (Shulkin, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystography, anterograde (unlabeled use):",
"     </b>",
"     I.V.: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg); minimum: 1 mCi (37 MBq); maximum: 10 mCi (370 MBq) (ACR, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      GFR estimation (unlabeled use):",
"     </b>",
"     I.V.: 0.2-0.5 mCi (7.4-18.5 MBq) (ACR, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Evaluation of renovascular hypertension (unlabeled use):",
"     </b>",
"     I.V.: 0.1 mCi/kg (3.7 MBq/kg) (Taylor, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Kidney imaging (unlabeled use):",
"     </b>",
"     I.V.: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg); minimum: 1 mCi (37 MBq); maximum: 10 mCi (370 MBq) (ACR, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystography, retrograde (unlabeled use):",
"     </b>",
"     Intracatheter (urethral): 0.5-1 mCi (18.5-37 MBq); may consider 0.25-0.5 mCi (9.25-18.5 MBq) in infants and toddlers (ACR, 2010); do not exceed 1 mCi (37MBq) per bladder-filling cycle (Gelfand, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13736046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aerosol: A disposable nebulizer is required; can be performed at the bedside, preferably when the patient is in an upright position.",
"     <b>",
"      Note:",
"     </b>",
"     Actual dose delivered to the lungs is about 2% to 5% of the dose in nebulizer.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13735868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kidney imaging; brain imaging; renal perfusion assessment; GFR estimation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13735869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lung scintigraphy for diagnosis of pulmonary embolism; evaluation of renovascular hypertension; cystography; diuretic renography; CSF leak detection; pediatric brain imaging; pediatric kidney imaging; pediatric GFR estimation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13736033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13736124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Facial edema, hypertension (transient blood pressure increase)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythema, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13736045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Acute hypersensitivity reactions may occur.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13736082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13736083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed. Small amounts of radioactive material cross the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13736095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13736121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of radioactive material (0.01% to 7.9%) is found in breast milk if breast-feeding has not been interrupted. This amount is so low that interruption of breast-feeding is not considered necessary with intravenous administration (U.S. Nuclear Regulatory Commission, 1977).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology (ACR) and Society for Pediatric Radiology (SPR), \"ACR-SPR Practice Guideline for the Performance of Adult and Pediatric Renal Scintigraphy,\" 2008. Available at file://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/nuc_med/renal_scintigraphy.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology (ACR), Society for Pediatric Radiology (SPR), and Society of Nuclear Medicine (SNM), \"ACR-SPR-SNM Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography,\" 2010. Available at file://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/pediatric/radionuclide_cystography.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donohoe KJ, Frey KA, Gerbaudo VH, et al, \"Procedure Guideline for Brain Death Scintigraphy,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2003, 44(5):846-51. Available at file://interactive.snm.org/docs/pg_ch20_0403.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/36/28227/abstract-text/12732688/pubmed\" id=\"12732688\" target=\"_blank\">",
"        12732688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gelfand MJ, Parisi MT, Treves ST, et al, \"Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2011, 52(2):318-22. Available at file://jnm.snmjournals.org/content/52/2/318.full.pdf+html",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/36/28227/abstract-text/21233182/pubmed\" id=\"21233182\" target=\"_blank\">",
"        21233182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kowalsky RJ and Falen SW,",
"      <i>",
"       Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine",
"      </i>",
"      , 2nd ed, Washington, DC: American Pharmacists Association, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulkin BL, Mandell GA, Cooper JA, et al, \"Procedure Guideline for Diuretic Renography in Children 3.0,\"",
"      <i>",
"       J Nucl Med Technol",
"      </i>",
"      , 2008, 36(3):162-8. Available at file://interactive.snm.org/docs/162.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/36/28227/abstract-text/18765635/pubmed\" id=\"18765635\" target=\"_blank\">",
"        18765635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Society of Nuclear Medicine, &ldquo;SNM Practice Guideline for Lung Scintigraphy V4.0,&rdquo; 2011. Available at file://interactive.snm.org/docs/Lung_Scintigraphy_V4_Final.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stabin MG and Breitz HB, \"Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry,\"",
"      <i>",
"       J Nucl Med",
"      </i>",
"      , 2000, 41(5):863-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/36/28227/abstract-text/10809203/pubmed\" id=\"10809203\" target=\"_blank\">",
"        10809203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor AT Jr, Blaufox MD, Dubovsky EV, et al, \"Society of Nuclear Medicine Procedure Guideline for Diagnosis of Renovascular Hypertension,\" 2003. Available at: file://interactive.snm.org/docs/pg_ch16_0403.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Nuclear Regulatory Commission, \"Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,\" 1977.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83326 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7EC3A6EE76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28227=[""].join("\n");
var outline_f27_36_28227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13734606\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13734607\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736154\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736265\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736046\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13735868\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13735869\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736033\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736124\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736045\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736082\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736083\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736095\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13736121\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/59/6067?source=related_link\">",
"      Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28228="Mild acute rejection";
var content_f27_36_28228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ITx mild acute rejection (high power view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mononuclear inflammatory infiltrate is present with crypt inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Farrukh Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28228=[""].join("\n");
var outline_f27_36_28228=null;
var title_f27_36_28229="Irbesartan and hydrochlorothiazide: Patient drug information";
var content_f27_36_28229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Irbesartan and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/19/20791?source=see_link\">",
"     see \"Irbesartan and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avalide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avalide&reg;;",
"     </li>",
"     <li>",
"      CO Irbesartan HCT;",
"     </li>",
"     <li>",
"      Irbesartan-HCTZ;",
"     </li>",
"     <li>",
"      PMS-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      Ran&trade;-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      ratio-Irbesartan HCTZ;",
"     </li>",
"     <li>",
"      Sandoz-Irbesartan HCT;",
"     </li>",
"     <li>",
"      Teva-Irbesartan HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702323",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to irbesartan, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3008203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a block in the kidneys' arteries or other very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10772 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28229=[""].join("\n");
var outline_f27_36_28229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184390\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184391\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020690\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020692\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020691\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020696\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020697\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020699\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020694\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020695\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020700\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020701\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/19/20791?source=related_link\">",
"      Irbesartan and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28230="Prednisone: Patient drug information";
var content_f27_36_28230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prednisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     see \"Prednisone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     see \"Prednisone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PredniSONE Intensol&trade;;",
"     </li>",
"     <li>",
"      Rayos&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prednisone&reg;;",
"     </li>",
"     <li>",
"      Novo-Prednisone;",
"     </li>",
"     <li>",
"      Winpred&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat COPD (chronic obstructive pulmonary disease).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling from autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling in parts of the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sarcoidosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prednisone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10992 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28230=[""].join("\n");
var outline_f27_36_28230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022324\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022326\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022325\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022330\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022331\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022333\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022328\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022329\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022334\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022335\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=related_link\">",
"      Prednisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=related_link\">",
"      Prednisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28231="IPH dilatation portal vein";
var content_f27_36_28231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic portal hypertension (IPH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Masson's trichrome stain of a liver biopsy specimen in a patient with IPH showing marked abnormal dilatation of a portal vein radicle. The dilation is evident when comparing the portal vein radicle to the relatively small bile duct (BD) and hepatic artery (HA) in the portal triad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rosa Miquel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28231=[""].join("\n");
var outline_f27_36_28231=null;
var title_f27_36_28232="Clinical manifestations and diagnosis of cysticercosis";
var content_f27_36_28232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of cysticercosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28232/contributors\">",
"     A Clinton White, Jr, MD, FACP, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28232/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28232/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/36/28232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysticercosis is caused by the larval stage (metacestode) of the pork tapeworm Taenia solium. Clinical syndromes related to this parasite are divided into neurocysticercosis (NCC) and extraneural cysticercosis. Neurocysticercosis, in turn, is divided into parenchymal and extraparenchymal forms. Extraparenchymal forms include intraventricular, subarachnoid, intraocular, and spinal disease.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of cysticercosis will be reviewed here. The epidemiology, life cycle, transmission and treatment of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=see_link\">",
"     \"Epidemiology, transmission and prevention of cysticercosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17865?source=see_link\">",
"     \"Treatment of cysticercosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=see_link\">",
"     \"Intestinal tapeworms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue cysticerci develop over a period of three to eight weeks following ingestion of T. solium eggs shed in the stool of a human tapeworm carrier. Cysticerci can develop at one or multiple sites; during the initial viable phase, cysticerci do not cause much inflammation in surrounding tissues. This phase of infection is usually asymptomatic and cysticerci typically remain in this stage for many years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=see_link\">",
"     \"Epidemiology, transmission and prevention of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taenia parasites have sophisticated means of evading destruction, and a number of mechanisms for host immune tolerance have been postulated. Metacestodes elaborate a variety of substances, including taeniaestatin (a parasite serine proteinase inhibitor), paramyosin, sulfated polysaccharides, and secretory proteases, that inhibit or divert host inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/1\">",
"     1",
"    </a>",
"    ]. Taeniaestatin may also interfere with lymphocyte proliferation and macrophage function, thereby inhibiting normal cellular immune defenses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/1\">",
"     1",
"    </a>",
"    ]. Secreted proteases degrade host molecules including cytokines. In addition, humoral antibodies do not kill the mature metacestode.",
"   </p>",
"   <p>",
"    Eventually (after a variable number of years) the cysts degenerate and lose their ability to modulate the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2\">",
"     2",
"    </a>",
"    ]. Host immune and inflammatory cells attack the cysticercus, which leads to the appearance of edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contrast enhancement on imaging studies. This inflammatory response is associated with onset of seizures. Host inflammatory molecules such as Substance P may be key mediators of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultimately, the cystic lesions either resolve or form a calcified granuloma. When present, the calcifications are associated with recurrent seizures, although the mechanism of seizures associated with calcified lesions is not clear. Seizures may result from inflammation, perhaps from intermittent antigen release, or from scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Alternatively, changes in brain plasticity and scarring (eg, hippocampal sclerosis) may result in epileptogenic foci [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Studies have highlighted a potential role of matrix metalloproteinases in the pathogenesis of seizures in neurocysticercosis, especially in patients with calcified lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to parenchymal disease, which is associated with seizures, extraparenchymal disease is associated with symptoms of hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Cysticerci in the ventricles frequently become trapped in the foramena or aqueduct, causing obstructive hydrocephalus. When cysticerci develop in the subarachnoid space, they may enlarge to cause mass effect (especially when found in the Sylvian Fissure) or an inflammatory response may lead to chronic arachnoiditis. Arachnoiditis may be accompanied by communicating hydrocephalus, vasculitis, meningitis, and strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with multiple cysts frequently have cysts in more than one location, and it is not uncommon to have viable, inflamed, and calcified lesions present in the same patient.",
"   </p>",
"   <p>",
"    Some experts have termed cysticerci as \"active\" if they are viable or in the process of degenerating. If calcified granulomas are visualized radiographically in the absence of cysticerci the lesions are considered \"inactive.\" Active and inactive cysts may be present in the same patient simultaneously. However, these terms do not correlate with symptoms or the host inflammatory response and probably should be abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations depend upon whether the cysts are localized to the brain parenchyma, the extraparenchymal tissues, or both. In general, parenchymal cysts are associated with seizures and headache, while extraparenchymal cysts are associated with symptoms of elevated intracranial pressure (eg, headache, nausea, and vomiting) and may be accompanied by altered mental status. Other less common manifestations include mass effect, altered vision, focal neurologic signs, altered mental status, and meningitis. Fever is not typically present. Neurologic examination usually does not demonstrate focal signs in the absence of mass effect or stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Parenchymal NCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenchymal cystic or enhancing lesions are the most common form of NCC in hospital-based series and is present in &gt;60 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,11-14\">",
"     2,11-14",
"    </a>",
"    ]. The onset of symptomatic NCC has been estimated to peak at three to five years after infection, but it can be delayed for &gt;30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ]. Later onset may be due to calcified lesions.",
"   </p>",
"   <p>",
"    Evaluation of imaging studies in endemic areas has suggested that most parenchymal neurocysticercal infections never cause symptoms; as a result, many cases are found incidentally during imaging procedures or are never diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. However, some small nodular calcifications (usually 1 to 10 mm in diameter) not previously thought to be associated with clinical manifestations may be an important cause of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/5,17,20,21\">",
"     5,17,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations depend on the location and number of parasites and the associated inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,14,22\">",
"     2,14,22",
"    </a>",
"    ]. Seizures are the most common clinical manifestations of parenchymal cysticercosis and are usually focal but may have secondary generalization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,12,13,20,23-25\">",
"     2,12,13,20,23-25",
"    </a>",
"    ]. Children with neurocysticercosis typically present with seizures and a single enhancing lesion; this presentation is also very common among adults (eg, in India and the Americas). In many endemic countries, NCC is the most common cause of adult-onset seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,20,22\">",
"     2,20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of massive numbers of cysts in the brain parenchyma, an intense immune response with diffuse brain edema can cause a clinical picture resembling encephalitis. This syndrome can present with seizures, headache, nausea and vomiting, impaired consciousness, reduced visual acuity, and occasionally fever. It can occur spontaneously or can be provoked by therapy that causes a large number of cysts to degenerate simultaneously. This manifestation is most common in children and young women.",
"   </p>",
"   <p>",
"    The prognosis varies with the number of cysticerci and degree of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with single enhancing lesions have a more favorable prognosis than those with multiple viable cysticerci.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extraparenchymal NCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraparenchymal cysticerci can occur in the intraventricular or subarachnoid space. Hydrocephalus appears to be more common in adults than in children (who are more likely to have parenchymal disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/11\">",
"     11",
"    </a>",
"    ]. Other manifestations of extraparenchymal NCC include spinal and ocular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intraventricular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysticerci develop in the ventricular system (as free floating cysts in the ventricular cavity or attached to the choroid plexus) in 10 to 20 percent of patients presenting for clinical attention. Symptoms typically develop when cysticerci become lodged in the ventricular outflow tracks, with consequent obstructive hydrocephalus and increased intracranial pressure of gradual or acute onset [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/13,14,26\">",
"     13,14,26",
"    </a>",
"    ]. Associated symptoms include headaches, nausea, and vomiting, altered mental status, and decreased visual acuity associated with papilledema. Less frequent symptoms include seizures and focal neurologic signs. Mobile cysts in the fourth ventricle can occasionally cause intermittent obstruction, leading to episodes of sudden loss of consciousness related to head movements (Bruns' syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Subarachnoid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cysticerci that lodge in the subarachnoid space of the fissures or basilar cisterns can generate an inflammatory response leading to chronic arachnoiditis, which may be accompanied by hydrocephalus, meningitis, stroke, and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/10,13,14,26,28\">",
"     10,13,14,26,28",
"    </a>",
"    ]. Patients with basal subarachnoid neurocysticercosis are more likely to have involvement of the spinal subarachnoid space than patients with intraparenchymal brain cysts only [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary occlusion of the foramina of Luschka or Magendie can lead to obstructive hydrocephalus. In addition, meningeal inflammation and leptomeningeal thickening at the base of the brain can lead to visual field defects and cranial nerve palsies due to entrapment of the cranial nerves arising from the brainstem. Vascular involvement can lead to proliferative angiitis and vascular obstruction with secondary cerebral infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/10,28,30,31\">",
"     10,28,30,31",
"    </a>",
"    ]. Focal neurologic motor signs, ataxia, and sensory dysfunction can ensue; this presentation tends to be associated with a relatively poor prognosis.",
"   </p>",
"   <p>",
"    Racemose cysticercosis is an older term for cysticercosis characterized by proliferating lobulated cysts without scolices, which are usually found in the subarachnoid space. These cysticerci are thought to undergo disproportionate growth of their membrane with extensions of membranes that group in clusters, resembling bunches of grapes. It is very difficult to distinguish this form from other forms of subarachnoid cysticercosis clinically or radiographically.",
"   </p>",
"   <p>",
"    Cysticerci in the subarachnoid space may grow to 10 cm or larger. This is particularly common with cysticerci in the Sylvian fissure, since they are not limited by pressure from the brain parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. These cysticerci, termed \"giant cysticerci\", and accompanying inflammation can cause mass effect and focal neurologic defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spinal cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord involvement occurs in approximately 1 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In addition, many cases with intracranial subarachnoid cysticercosis also have spinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/29\">",
"     29",
"    </a>",
"    ]. Spinal cysticerci are usually located in the subarachnoid space where they can cause inflammatory and demyelinating changes in the peripheral nerve roots. Patients typically present with radicular pain, paresthesias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sphincter disturbances. Neurological deficits vary with the location of the lesion and may not be distinguishable from other spinal cord lesions on clinical grounds alone.",
"   </p>",
"   <p>",
"    Less commonly, intramedullary cysticercosis can occur and may be associated with transverse myelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ocular cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular cysticercosis occurs in approximately 1 to 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with ocular cysticercosis may have involvement of the subretinal space, vitreous humor, anterior chamber, conjunctiva or extraocular muscles. Symptoms may include impaired vision, recurrent eye pain and diplopia.",
"   </p>",
"   <p>",
"    Patients with subretinal cysticerci may be considered to have neurocysticercosis; the presence of cysticerci in the anterior chamber of the eye is extraneural cysticercosis. Although many patients are asymptomatic, inflammation around degenerating cysticerci can threaten vision by causing chorioretinitis, retinal detachment, or vasculitis. Ocular cysticercosis should be excluded by an ophthalmologic examination in all patients with NCC prior to initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extraneural cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraneural cysticercosis may involve a wide range of tissues, but is typically diagnosed in the setting of muscle or subcutaneous tissue involvement. Cardiac cysts have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2\">",
"     2",
"    </a>",
"    ]. Depending on their location, these may be asymptomatic or may result in arrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conduction abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Subcutaneous and intramuscular cysticercosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle or subcutaneous cysticercosis is more common in patients from Asia and Africa than from Latin America. It is not known whether oncospheres actively migrate to specific tissues or enter tissues passively during high blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may notice subcutaneous nodules 0.5 to 2.0 cm in diameter; cysticerci at these sites are usually asymptomatic but may cause discomfort when inflamed. Intramuscular cysts often undergo calcification and may be detected incidentally as \"cigar-shaped calcifications\" when radiographs are performed for unrelated reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2\">",
"     2",
"    </a>",
"    ]. In the setting of extensive muscle involvement, acute myopathy can develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of neurocysticercosis is largely based on clinical presentation and radiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/2,14,35,36\">",
"     2,14,35,36",
"    </a>",
"    ]. Serologic tests can be helpful but are not always necessary; invasive procedures such as brain biopsy are rarely required.",
"   </p>",
"   <p>",
"    The extent of diagnostic evaluation needed depends upon the clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"     36",
"    </a>",
"    ]. For example, in a patient from an endemic area presenting with seizures (in the absence of focal neurologic findings, fever, sweats, or evidence of other diseases) together with a typical single enhancing lesion (without midline shift) on brain imaging, the likelihood of the diagnosis of neurocysticercosis is very high [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. Further diagnostic procedures may not be necessary. However, for circumstances in which the diagnosis is less certain, additional diagnostic evaluation may be warranted, including serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=see_link\">",
"     \"Epidemiology, transmission and prevention of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnostic criteria have been proposed based on objective clinical, imaging, immunologic, and epidemiologic data (",
"    <a class=\"graphic graphic_table graphicRef78175 \" href=\"UTD.htm?15/7/15485\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"     36",
"    </a>",
"    ]. These include categories stratified on the basis of their diagnostic strength (absolute, major, minor and epidemiologic). Interpretation of these criteria permits definitive or probable degrees of diagnostic certainty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging is an important tool for diagnosis of neurocysticercosis and extraneural cysticercosis. Patients with suspected NCC should be evaluated with computed tomographic (CT) scan or magnetic resonance imaging (MRI) of the brain; CT is often sufficient for diagnostic purposes although MRI is helpful in some situations as discussed below. In addition, patients with basal subarachnoid NCC should undergo spine imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/29\">",
"     29",
"    </a>",
"    ]. The radiographic findings depend upon the location and stage of the lesion(s) and the host immune response.",
"   </p>",
"   <p>",
"    In parenchymal neurocysticercosis, cysticerci tend to lodge in the cerebral cortex or within the brainstem; displacement of midline structures is rare. Cystic and calcified lesions may be present in the same patient simultaneously. Viable cysts are round, nonenhancing hypodense lesions usually 5 to 20 mm in diameter. As the cyst begins to degenerate, the cyst wall increases in density and is often accompanied by edema or contrast enhancement. Subsequently, the cavity increases in density and may enhance with contrast. Following collapse of the cyst, a residual calcified granuloma may be visualized; calcifications are usually solid, nodular lesions 2 to 4 mm in diameter (range 1 to 10 mm).",
"   </p>",
"   <p>",
"    Less common findings of parenchymal NCC include involvement of the brainstem, cerebellum or basal ganglia, mass effect, diffuse cerebral edema, cerebral infarction, giant cysts measuring &gt;20 cm and multiple cysts numbering &gt;50.",
"   </p>",
"   <p>",
"    Extraparenchymal NCC may be visualized with cerebral imaging depending upon the location of the lesions. Manifestations may include intraventricular cysts, subarachnoid cysts, leptomeningeal enhancement, or hydrocephalus with ventricular enlargement. CT imaging is also useful for diagnosis of cysticercal infestation of eye and extraocular muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/34,38\">",
"     34,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of a scolex in a cystic lesion is the only pathognomonic radiographic finding. Scolices appear as rounded or elongated bright nodules 2 to 4 mm in diameter within the cyst cavity. The scolex is usually not identifiable in calcified lesions, but occasionally may be visible on MRI. Other radiographic findings highly suggestive of neurocysticercosis include cystic lesions, enhancing lesions and parenchymal brain calcifications. Radiographic findings compatible with neurocysticercosis include hydrocephalus, leptomeningeal enhancement, and myelograms with contrast filling defects.",
"   </p>",
"   <p>",
"    CT scanning is less expensive than MRI, is excellent for detecting calcifications, and is often sufficient to make the diagnosis. MRI is useful for detecting relatively small lesions as well as intraventricular and subarachnoid lesions. It is also helpful for evaluating degenerative changes, edema around calcific lesions, and for visualizing scolices within calcified lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36,38-44\">",
"     36,38-44",
"    </a>",
"    ]. While the cystic lesions are usually visible without contrast, contrast facilitates visualization of images. FLAIR images on MRI are particularly helpful in identifying cysticerci in the parenchyma, and FIESTA images are useful for identifying cysticerci in cerebrospinal fluid. Parenchymal cysticerci eventually degenerate spontaneously or after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    . Thus, resolution of lesions either spontaneously or after antiparasitic therapy is thought to be strongly suggestive of neurocysticercosis.",
"   </p>",
"   <p>",
"    Plain radiography can be useful for evaluation of extraneural cysticercosis such as calcified lesions (\"cigar-shaped calcifications\") in muscle or subcutaneous tissue, although CT is more sensitive for these findings. In a study of 25 patients with calcified intraparenchymal brain lesions, for example, non-contrast CT imaging of the thighs demonstrated one or more muscle calcifications consistent with extraneural cysticercosis in 52 percent of cases; calcifications were visible on plain radiographs in only 46 percent of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For evaluation of spinal cord lesions MRI is superior to CT; myelography may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is an important adjunct in cases of suspected cysticercosis when neuroimaging studies are not diagnostic. However, negative serology does not exclude the diagnosis in patients with a compatible clinical presentation and radiographic findings. In addition, for individuals from highly endemic areas with positive serologic results it is also important to consider the possibility of previous infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extraneural cysticercosis.",
"   </p>",
"   <p>",
"    A number of serologic tests have been developed for serum and CSF. Some assays detect anticysticercal antibodies; others identify cysticercal antigens. A variety of techniques can be used to detect antibody to T. solium, including enzyme linked immunosorbent assay (ELISA), complement fixation (CF), radioimmunoassay, hemagglutination and immunoblot. In general, assays for detection of antibody to specific T. solium antigens are preferable to assays employing unfractionated antigens, which have poor specificity and sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Although the latter assays are widely available commercially, they are not favored by experts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The test of choice for antibody detection is the enzyme-linked immunoelectrotransfer blot assay (EITB) developed by the Centers for Disease Control (also available in commercial laboratories) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"     36",
"    </a>",
"    ]. The EITB assay can be performed on serum or CSF but sensitivity is usually higher with serum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/48\">",
"     48",
"    </a>",
"    ]. It uses affinity-purified glycoprotein antigens fractionated by electrophoresis and has higher sensitivity and specificity than older ELISA tests (83 to 100 percent and close to 100 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Rare false positive results have been noted in subjects with a single band at 50 kDa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/49\">",
"     49",
"    </a>",
"    ]. All of the antigens recognized in the EITB assay have been cloned and incorporated into ELISA and immunoblot assays; it is likely these will eventually replace assays requiring parasite material [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic performance of the EITB can vary in different patient populations depending on the activity of the cyst and number of lesions. In a study of 50 patients with pathologically confirmed neurocysticercosis, for example, detectable antibodies were more readily observed in patients with two or more lesions than patients with a single lesion (94 versus 28 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with only calcified cysts (single or multiple) were also less likely to have positive EITB results than those with noncalcified, enhancing lesions. In addition, antibodies can persist for years following death of the parasites, so a positive antibody test does not necessarily indicate the presence of live parasites or active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of new assays are being developed. Studies of monoclonal antibody-based ELISA tests for detection of parasite antigens have demonstrated detection of circulating and CSF antigen and may be useful for both diagnosis as well as post therapeutic monitoring (parasite antigen levels typically fall by three months after successful treatment). The sensitivity and specificity of the assays is similar to EITB, but there is a closer correlation between circulating antigen detection and CT scanning results during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/44,52-56\">",
"     44,52-56",
"    </a>",
"    ]. Other assays are under development include antigen detection tests to detect live parasites and polymerase chain reaction assays [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/10,14,50,57\">",
"     10,14,50,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Funduscopic exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct visualization of the parasite by funduscopic examination is pathognomonic for diagnosis of cysticercosis (",
"    <a class=\"graphic graphic_table graphicRef78175 \" href=\"UTD.htm?15/7/15485\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"     36",
"    </a>",
"    ]. Although ocular cysticercosis is relatively uncommon and many patients are asymptomatic, inflammation around degenerating cysticerci can threaten vision, particularly in the setting of antiparasitic therapy. For this reason, ocular cysticercosis should be excluded by an ophthalmologic examination in all patients with NCC prior to initiating therapy. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Ocular cysticercosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17865?source=see_link\">",
"     \"Treatment of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Spinal fluid studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lumbar puncture for CSF examination is usually not necessary for the diagnosis of NCC but can be helpful for excluding other diagnoses. This procedure is contraindicated in the setting of increased intracranial pressure.",
"   </p>",
"   <p>",
"    If a lumbar puncture is performed in the setting of parenchymal lesions, examination of the CSF typically demonstrates mildly elevated white cell counts with normal concentrations of glucose and protein. In the setting of active arachnoiditis or ventriculitis, however, pleocytosis with markedly elevated protein concentrations and decreased glucose concentrations may be observed. Cell counts may demonstrate a predominance of mononuclear cells, neutrophils, or eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/58\">",
"     58",
"    </a>",
"    ]. The differential diagnosis of an eosinophilic CSF pleocytosis includes coccidioidomycosis, gnathostomiasis, baylisascariasis, angiostrongyloidiasis, and non-infectious causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=see_link\">",
"     \"Eosinophilic meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The enzyme-linked immunoelectrotransfer blot assay (EITB) assay can be performed on serum or CSF but sensitivity is usually higher with serum. Antigen detection assays are more sensitive with CSF. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Serology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain biopsy is warranted only in rare cases for which non-invasive testing is insufficient to establish the diagnosis of cysticercosis. However, excisional biopsy of a skin or muscle lesion can be useful for diagnosis of extraneural cysticercosis.",
"   </p>",
"   <p>",
"    A viable cysticercus appears as a translucent fluid-filled membrane (about 5 to 10 mm in diameter) containing a solid larval tapeworm scolex (2 mm in length). Histopathology typically demonstrates membranous walls filled with fluid. Less often, scolices (composed of rudimentary bodies and heads with suckers and hooks) may also be visualized; this finding is pathognomonic for the diagnosis of cysticercosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/59\">",
"     59",
"    </a>",
"    ]. The degree of inflammation can be variable. As the parasite degenerates, the cyst cavity collapses and the parasite walls are gradually engulfed in granulomatous inflammation. The scolex is usually not identifiable in calcified lesions, but occasionally may visible on MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with cysticercosis have no specific diagnostic finding on routine blood counts and liver function tests. Peripheral eosinophilia is usually absent. Stool examination is insensitive since most individuals with cysticercosis do not have a viable intestinal tapeworm at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable clinical approach to diagnosis of cysticercosis is to begin with CT imaging of the brain and serology with enzyme-linked immunoelectrotransfer blot assay (EITB). If the CT findings are inconclusive in the setting of high clinical suspicion, subsequent MRI imaging is appropriate for evaluation of small lesions, subarachnoid or intraventricular lesions, and scolex visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28232/abstract/18,41\">",
"     18,41",
"    </a>",
"    ]. If the appearance on radiographic imaging is nonspecific and serologic tests are negative, it may not be possible to differentiate NCC from other brain lesions such as abscess or malignancy.",
"   </p>",
"   <p>",
"    Ocular cysticercosis should be excluded by an ophthalmologic examination in all patients with NCC prior to initiating therapy. No routine laboratory studies are necessary; patients do not often have significant peripheral eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that can mimic single or multiple ring or nodular enhancing lesions include tuberculomas, pyogenic brain abscesses, mycotic granulomas and primary or metastatic brain tumors. Cystic lesions of the brain include cystic echinococcosis, coenurosis and cystic gliomas and glioblastomas. Parenchymal brain calcifications may be found in the setting of metabolic disorders, vascular malformations, intracranial neoplasms, congenital anomalies and other infections. Arachnoiditis with ventricular enlargement may be seen in the setting of tuberculous and fungal meningitis and meningeal carcinomatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical syndromes related to cysticercosis are divided into neurocysticercosis (NCC) and extraneural cysticercosis. Neurocysticercosis, in turn, is divided into parenchymal and extraparenchymal forms. Extraparenchymal forms include intraventricular, subarachnoid, intraocular, and spinal disease. Extraneural cysticercosis typically involves muscle or subcutaneous tissue. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue cysticerci develop over a period of three to eight weeks following ingestion of T. solium eggs shed in the stool of a human tapeworm carrier. Cysticerci can develop at one or multiple sites; during the initial viable phase they do not cause much inflammation in surrounding tissues. Eventually the cystic lesions degenerate and either resolve or form a calcified granuloma. Calcified and cystic lesions may be present in the same patient simultaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations depend upon whether the cysts are localized to the brain parenchyma, the extraparenchymal tissues, or both. In general, parenchymal cysts are associated with seizures while extraparenchymal cysts are associated with symptoms of elevated intracranial pressure (eg, headache, nausea, and vomiting) and may be accompanied by altered mental status. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reasonable clinical approach to diagnosis of cysticercosis is to begin with CT imaging of the brain and serology with enzyme-linked immunoelectrotransfer blot assay (EITB). If the CT findings are inconclusive in the setting of high clinical suspicion, subsequent MRI imaging is appropriate for evaluation of small lesions, brainstem or intraventricular lesions, and scolex visualization. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification of a scolex is the only pathognomonic radiographic finding. Radiographic findings highly suggestive of neurocysticercosis include cystic lesions, enhancing lesions, and parenchymal brain calcifications. Radiographic findings compatible with neurocysticercosis include hydrocephalus, leptomeningeal enhancement, and myelograms with contrast filling defects. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serologic test of choice for antibody detection is the enzyme-linked immunoelectrotransfer blot assay (EITB). Its diagnostic performance can vary depending on the activity of the cyst and number of lesions. A positive antibody test does not necessarily indicate the presence of live parasites or active disease since antibodies can persist for years following death of the parasites. Antigen detection assays may help distinguish viable cysticerci. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular cysticercosis should be excluded by an ophthalmologic examination in all patients with NCC prior to initiating therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ocular cysticercosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     White AC, Jr, Robinson P, Kuhn R. Taenia solium cysticercosis: Host-parasite interactions and the immune response. In: Immunopathogenetic Aspects of Disease Induced by Helminth Parasites, Freedman DO (Ed), Karger, Basel 1997. p.209.",
"    </li>",
"    <li>",
"     Garcia HH, Coyle CM, White AC Jr. Cysticercosis. In: Tropical Infectious Diseases: Principles, Pathogens, and Practice, Guerrant RL, Walker DH, Weller PF.  (Eds), Churchil-Livingstone, Philadelphia 2011. p.815.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/3\">",
"      Stringer JL, Marks LM, White AC Jr, Robinson P. Epileptogenic activity of granulomas associated with murine cysticercosis. Exp Neurol 2003; 183:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/4\">",
"      Robinson P, Garza A, Weinstock J, et al. Substance P causes seizures in neurocysticercosis. PLoS Pathog 2012; 8:e1002489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/5\">",
"      Nash TE, Del Brutto OH, Butman JA, et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004; 62:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/6\">",
"      Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol 2008; 7:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/7\">",
"      Singla M, Singh P, Kaushal S, et al. Hippocampal sclerosis in association with neurocysticercosis. Epileptic Disord 2007; 9:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/8\">",
"      Rathore C, Thomas B, Kesavadas C, Radhakrishnan K. Calcified neurocysticercosis lesions and hippocampal sclerosis: potential dual pathology? Epilepsia 2012; 53:e60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/9\">",
"      Gupta RK, Awasthi R, Rathore RK, et al. Understanding epileptogenesis in calcified neurocysticercosis with perfusion MRI. Neurology 2012; 78:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/10\">",
"      Garcia HH, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005; 72:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/11\">",
"      S&aacute;enz B, Ru&iacute;z-Garcia M, Jim&eacute;nez E, et al. Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J 2006; 25:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/12\">",
"      Singhi P, Ray M, Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol 2000; 15:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/13\">",
"      Serpa JA, Graviss EA, Kass JS, White AC Jr. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 2011; 90:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/14\">",
"      Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol 2011; 7:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/15\">",
"      del la Garza Y, Graviss EA, Daver NG, et al. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg 2005; 73:766.",
"     </a>",
"    </li>",
"    <li>",
"     Dixon HB, Lipscomb FM. Cysticercosis: An analysis and follow-up of 450 cases, Her Majesty's Stationary Service, London 1961.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/17\">",
"      Montano SM, Villaran MV, Ylquimiche L, et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005; 65:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/18\">",
"      Fleury A, Gomez T, Alvarez I, et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003; 22:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/19\">",
"      Prasad A, Gupta RK, Pradhan S, et al. What triggers seizures in neurocysticercosis? A MRI-based study in pig farming community from a district of North India. Parasitol Int 2008; 57:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/20\">",
"      Medina MT, Dur&oacute;n RM, Mart&iacute;nez L, et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salam&aacute; Study. Epilepsia 2005; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/21\">",
"      Garcia-Noval J, Moreno E, de Mata F, et al. An epidemiological study of epilepsy and epileptic seizures in two rural Guatemalan communities. Ann Trop Med Parasitol 2001; 95:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/22\">",
"      Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006; 67:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/23\">",
"      Del Brutto OH, Santiba&ntilde;ez R, Noboa CA, et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992; 42:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/24\">",
"      Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002; 59:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/25\">",
"      Singh G, Singh P, Singh I, et al. Epidemiologic classification of seizures associated with neurocysticercosis: observations from a sample of seizure disorders in neurologic care in India. Acta Neurol Scand 2006; 113:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/26\">",
"      Rangel-Castilla L, Serpa JA, Gopinath SP, et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009; 80:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/27\">",
"      Torres-Corzo J, Rodriguez-della Vecchia R, Rangel-Castilla L. Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy. J Neurosurg 2006; 104:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/28\">",
"      Viola GM, White AC Jr, Serpa JA. Hemorrhagic cerebrovascular events and neurocysticercosis: a case report and review of the literature. Am J Trop Med Hyg 2011; 84:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/29\">",
"      Callacondo D, Garcia HH, Gonzales I, et al. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology 2012; 78:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/30\">",
"      Barinagarrementeria F, Cant&uacute; C. Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study. Stroke 1998; 29:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/31\">",
"      Jha S, Kumar V. Neurocysticercosis presenting as stroke. Neurol India 2000; 48:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/32\">",
"      Alsina GA, Johnson JP, McBride DQ, et al. Spinal neurocysticercosis. Neurosurg Focus 2002; 12:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/33\">",
"      Bandres JC, White AC Jr, Samo T, et al. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis 1992; 15:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/34\">",
"      Pushker N, Bajaj MS, Chandra M. Ocular and orbital cysticercosis. Acta Ophthalmol Scand 2001; 79:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/35\">",
"      Garcia HH, Del Brutto OH, Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/36\">",
"      Del Brutto OH, Rajshekhar V, White AC Jr, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001; 57:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/37\">",
"      Rajshekhar V, Chandy MJ. Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. Acta Neurol Scand 1997; 96:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/38\">",
"      Sharma T, Sinha S, Shah N, et al. Intraocular cysticercosis: clinical characteristics and visual outcome after vitreoretinal surgery. Ophthalmology 2003; 110:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/39\">",
"      Chang KH, Han MH. MRI of CNS parasitic diseases. J Magn Reson Imaging 1998; 8:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/40\">",
"      Zee CS, Go JL, Kim PE, DiGiorgio CM. Imaging of neurocysticercosis. Neuroimaging Clin N Am 2000; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/41\">",
"      Garc&iacute;a HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop 2003; 87:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/42\">",
"      Castillo M. Imaging of neurocysticercosis. Semin Roentgenol 2004; 39:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/43\">",
"      Gupta RK, Kumar R, Chawla S, Pradhan S. Demonstration of scolex within calcified cysticercus cyst: its possible role in the pathogenesis of perilesional edema. Epilepsia 2002; 43:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/44\">",
"      Garcia HH, Harrison LJ, Parkhouse RM, et al. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru. Trans R Soc Trop Med Hyg 1998; 92:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/45\">",
"      Bustos JA, Garcia HH, Dorregaray R, et al. Detection of muscle calcifications by thigh CT scan in neurocysticercosis patients. Trans R Soc Trop Med Hyg 2005; 99:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/46\">",
"      Proa&ntilde;o-Narvaez JV, Meza-Lucas A, Mata-Ruiz O, et al. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol 2002; 40:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/47\">",
"      Gekeler F, Eichenlaub S, Mendoza EG, et al. Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur J Clin Microbiol Infect Dis 2002; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/48\">",
"      Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991; 164:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/49\">",
"      Kojic EM, White AC Jr. A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis 2003; 36:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/50\">",
"      Lee YM, Handali S, Hancock K, et al. Serologic diagnosis of human Taenia solium cysticercosis by using recombinant and synthetic antigens in QuickELISA&trade;. Am J Trop Med Hyg 2011; 84:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/51\">",
"      Garcia HH, Gilman RH, Catacora M, et al. Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis Working Group in Peru. J Infect Dis 1997; 175:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/52\">",
"      Garcia HH, Parkhouse RM, Gilman RH, et al. Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients. Trans R Soc Trop Med Hyg 2000; 94:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/53\">",
"      Garcia HH, Gonzalez AE, Gilman RH, et al. Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis. Am J Trop Med Hyg 2002; 66:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/54\">",
"      Fleury A, Hern&aacute;ndez M, Avila M, et al. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry 2007; 78:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/55\">",
"      Rodriguez S, Dorny P, Tsang VC, et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 2009; 199:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/56\">",
"      White AC Jr. New developments in the management of neurocysticercosis. J Infect Dis 2009; 199:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/57\">",
"      Michelet L, Fleury A, Sciutto E, et al. Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol 2011; 49:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28232/abstract/58\">",
"      Wang CH, Gao SF, Guo YP. Diagnostic significance of eosinophilia of the cerebrospinal fluid in cerebral cysticercosis. Chin Med J (Engl) 1993; 106:282.",
"     </a>",
"    </li>",
"    <li>",
"     Gutierrez Y. Cysticercosis, Coenurosis, and Sparganosis. In: Diagnostic Pathology of Parasitic Infection with Clinical Correlation, Gutierrez Y (Ed), Oxford University Press, Oxford 2000. p.635.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5678 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28232=[""].join("\n");
var outline_f27_36_28232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Parenchymal NCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extraparenchymal NCC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intraventricular cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Subarachnoid cysts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spinal cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ocular cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extraneural cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Subcutaneous and intramuscular cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Funduscopic exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Spinal fluid studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/7/15485\" title=\"table 1\">",
"      Diagnosis of cysticercosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=related_link\">",
"      Eosinophilic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15413?source=related_link\">",
"      Epidemiology, transmission and prevention of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=related_link\">",
"      Intestinal tapeworms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17865?source=related_link\">",
"      Treatment of cysticercosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28233="Treatment of primary dysmenorrhea in adult women";
var content_f27_36_28233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of primary dysmenorrhea in adult women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Roger P Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Andrew M Kaunitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28233/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/36/28233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea refers to the presence of recurrent, crampy, lower abdominal pain occurring during menses and in the absence of demonstrable disease. The management of women with primary dysmenorrhea will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of primary dysmenorrhea are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=see_link\">",
"     \"Primary dysmenorrhea in adult women: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28816153\">",
"    <span class=\"h2\">",
"     Goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is to provide adequate relief of pain. At a minimum, pain relief should be sufficient to allow the woman to perform most, if not all, of her usual activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28816178\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of primary dysmenorrhea can be initiated empirically. Laboratory tests, imaging studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laparoscopy are not required to definitively exclude causes of secondary dysmenorrhea when a detailed history and physical examination strongly support the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary dysmenorrhea in adult women: Clinical features and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=see_link&amp;anchor=H52181508#H52181508\">",
"     \"Primary dysmenorrhea in adult women: Clinical features and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General measures for management include patient education and reassurance. Treatment is supportive and should be guided by individual needs, as the severity of pain and degree of limitation of activity vary widely among women with dysmenorrhea (",
"    <a class=\"graphic graphic_table graphicRef65347 \" href=\"UTD.htm?22/16/22795\">",
"     table 1",
"    </a>",
"    ). The initial approach includes a discussion of nonpharmacologic interventions that can be helpful, such as application of a heat pack to the lower abdomen, exercise, and relaxation techniques. First-line pharmacologic therapy includes nonsteroidal anti-inflammatory drugs (NSAIDs)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    estrogen-progestin contraceptives (cyclic, long-cycle, or continuous), depending on the clinical needs of the patient. For women with primary dysmenorrhea desiring contraception, estrogen-progestin contraceptives are a logical choice. For women who prefer not to use hormonal treatment, NSAIDs are a logical choice. However, some women may need both types of treatment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Drug therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women who do not achieve adequate pain relief after three months of treatment with NSAIDs and hormonal contraceptives may have secondary dysmenorrhea due to endometriosis or other conditions. Options for these women include diagnostic laparoscopy or empiric GnRH agonist therapy. Intrauterine progestin delivery systems (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine system) have demonstrated some efficacy in women with dysmenorrhea secondary to either proven or suspected endometriosis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management of treatment failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no standard approach to treatment of documented primary dysmenorrhea inadequately relieved by NSAIDs and hormonal contraceptives. Patient specific factors, such as personal treatment goals and the cost and convenience of various treatments, should guide further therapy. The addition of transcutaneous electrical nerve stimulation (TENS) is an option. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Transcutaneous electrical nerve stimulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SELF-CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is reasonable to discuss self-care approaches to pain relief, especially for women who want to avoid drug therapy. Heat therapy is the most effective of these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two randomized trials, application of heat to the lower abdomen was effective for relief of dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Heat was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/1\">",
"     1",
"    </a>",
"    ] and more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/2\">",
"     2",
"    </a>",
"    ]. Most women find applying heat more cumbersome than taking oral medications, but it has no side effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 84 women to receive a heated patch plus placebo tablet, an unheated patch plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (400 mg), a heated patch plus ibuprofen, or an unheated patch and placebo tablet [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/1\">",
"       1",
"      </a>",
"      ]. Women assigned a heated abdominal patch or ibuprofen achieved comparable pain relief and significantly greater pain relief than those assigned an unheated patch and placebo tablet. The combination of a heated abdominal patch plus ibuprofen did not provide greater total pain relief than an unheated abdominal patch plus ibuprofen. However, the combination of a heated abdominal patch plus ibuprofen reduced the time to noticeable pain relief compared to an unheated abdominal patch plus ibuprofen.",
"     </li>",
"     <li>",
"      A second trial by the same group randomly assigned 367 women with dysmenorrhea to an abdominal heat wrap (40 degrees Celsius) which was worn for eight hours, a placebo wrap,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (1000 mg every five hours, four times per day for one day), or placebo pills [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/2\">",
"       2",
"      </a>",
"      ]. The heat wrap provided better pain relief than acetaminophen and was well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832071\">",
"    <span class=\"h2\">",
"     Exercise and sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review on the use of exercise for relief of dysmenorrhea included a single randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/3\">",
"     3",
"    </a>",
"    ] that provided evidence that exercise reduces menstrual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/4\">",
"     4",
"    </a>",
"    ]. Most observational studies have reported decreased prevalence of dysmenorrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improved symptomatology with exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the quality of this trial and these studies was low. As there are multiple health benefits to exercise, increasing physical activity is a reasonable approach, especially for sedentary women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Yoga [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/6\">",
"     6",
"    </a>",
"    ] and sexual activity may be helpful. Anecdotal experience suggests menses-related discomfort is relieved by orgasm in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832078\">",
"    <span class=\"h2\">",
"     Behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral interventions include attempts at modification of the way the patient thinks about her pain (eg, desensitization based procedures, hypnotherapy, imagery, coping strategies) and attempts at modification of her response to pain (eg, biofeedback, electromyographic training, Lamaze exercises, relaxation training). There is no high quality evidence to support or refute use of these modalities; a systematic review of randomized trials concluded some women may be helped by them [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diet and vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dietary changes and vitamin therapies has been reported to reduce the severity of menstrual pain, but data are limited to a few small studies. Although the limited available data appear promising, we would like to see confirmatory data from additional trials before suggesting these interventions for our patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one clinical trial, 33 women with primary dysmenorrhea and premenstrual symptoms were randomly assigned, in a crossover design, to receive a",
"      <strong>",
"       low fat-vegetarian diet",
"      </strong>",
"      for two months or a placebo dietary supplement pill [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/9\">",
"       9",
"      </a>",
"      ]. While on the vegetarian diet, the women noted a statistically significant decrease in menstrual pain intensity and duration, and they had a mean weight loss of 1.8 kg.",
"     </li>",
"     <li>",
"      A self-report study of dietary",
"      <strong>",
"       dairy intake",
"      </strong>",
"      in 127 female university students indicated that women who consumed three or four servings of dairy products per day had lower rates of dysmenorrhea than women who consumed no dairy products [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/10\">",
"       10",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Two randomized trials reported that",
"      <strong>",
"       vitamin E",
"      </strong>",
"      alone (500 units per day or 200 units twice per day, beginning two days before menses and continuing through the first three days of bleeding) was more effective than placebo for relieving dysmenorrhea in adolescents randomly assigned to either therapy, although both active drug and placebo reduced pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a systematic review including mostly single small trials,",
"      <strong>",
"       vitamin B1",
"      </strong>",
"      (100 mg daily),",
"      <strong>",
"       vitamin B6",
"      </strong>",
"      (200 mg daily), and",
"      <strong>",
"       fish oil",
"      </strong>",
"      <strong>",
"       supplement",
"      </strong>",
"      (1080 mg eicosapentaenoic acid, 720 mg docosahexaenoic acid, and 1.5 mg vitamin E) were each more effective for reducing pain than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial of 40 women with dysmenorrhea and a serum 25-hydroxyvitamin D (25OHD) level &lt;45",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      found that a single large dose of",
"      <strong>",
"       vitamin D3",
"      </strong>",
"      (oral, 300,000",
"      <span class=\"nowrap\">",
"       IU/1",
"      </span>",
"      mL) given five days prior to the expected first day of the menstrual cycle resulted in a statistically significant decrease in pain scores compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/14\">",
"       14",
"      </a>",
"      ]. However, this trial had several major limitations. The serum vitamin D level used was higher than the usual threshold for vitamin D supplementation (&lt;20",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      In addition, the safety of the administration of a large dose of vitamin D is uncertain; a large randomized trial found that administration of 500,000 IU resulted in more fractures than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/15\">",
"       15",
"      </a>",
"      ]. Given these limitations, additional studies are needed before this therapy is used clinically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence for achieving pain relief of primary dysmenorrhea is based on randomized trials of drug therapies. A placebo effect is particularly strong in primary dysmenorrhea trials, especially in the first month of treatment. However, the effects of placebo treatment appear to fade quickly. This was illustrated in a study where placebo therapy was associated with self-reported improvement in symptoms in the first, second, third, and fourth months of treatment in 84, 29, 16, and 10 percent of women, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/16\">",
"     16",
"    </a>",
"    ]. By comparison, active treatment with NSAIDs produced an 80 to 86 percent response rate that was maintained throughout the four months of treatment. These results underscore the importance of prospective, double-blind trials in which treatment is given over several cycles.",
"   </p>",
"   <p>",
"    NSAIDs and hormonal contraceptives represent the mainstays of drug therapy. No randomized trials have compared the efficacy of NSAIDs versus hormonal contraception for treatment of primary dysmenorrhea. If treatment with one of these agents fails after two or three months, we suggest a course of treatment with the other. Treatment with both hormonal contraception and NSAIDs may be effective in women who remain symptomatic on either drug alone. In addition, reevaluation of the original diagnosis is always indicated when therapies do not result in the anticipated level of response (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Management of treatment failure'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized trials has consistently demonstrated that NSAIDs effectively treat primary dysmenorrhea. In a systematic review of 73 randomized trials, NSAIDs were significantly more effective than placebo (OR 4.50, 95% CI 3.85-5.27) or paracetamol (OR 1.90, 95% CI 1.05-3.44) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/17\">",
"     17",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    It is unclear whether specific NSAIDS are more effective or safer than others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/17\">",
"     17",
"    </a>",
"    ]. Although some studies have not observed differences in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], others suggest that differences exist and that fenamates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    , tolfenamic acid, flufenamic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/10/21672?source=see_link\">",
"     meclofenamate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/5/25683?source=see_link\">",
"     bromfenac",
"    </a>",
"    ) may have slightly better efficacy than the phenylproprionic acid derivatives (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Both fenamates and phenylproprionic acid derivatives inhibit prostaglandin synthesis, but fenamates also block prostaglandin action, which may account for their enhanced effectiveness in some studies (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are insufficient data on which to base a recommendation for one class of agents or the other. One approach to treatment is to start with a phenylproprionic acid derivative prescribed at the upper end of the dose range. The doses of several NSAIDs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71912 \" href=\"UTD.htm?28/52/29516\">",
"     table 2",
"    </a>",
"    ). We prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    400 to 600 mg every four to six hours or 800 mg every eight hours to a maximum dose of 2400 mg per day, starting with the onset of symptoms or menses, and continue this dose for two or three days based on the patient's usual symptom pattern. An advantage of this approach is that phenylproprionic acid derivatives are relatively inexpensive, available without prescription, and of proven efficacy.",
"   </p>",
"   <p>",
"    If the phenylpropionic acid derivative does not produce sufficient improvement in pain symptoms, then a fenamate can be used (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    500 mg initially followed by 250 mg every six hours, with treatment typically limited to three days). Since NSAIDs are given for only a few days to young, generally healthy women, adverse effects tend to be less frequent than in other patient populations. General considerations regarding therapeutic use, drug interactions, and toxicities of NSAIDS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some COX-2 inhibitors have been approved for treatment of moderate to severe primary dysmenorrhea. These drugs are more expensive than nonspecific NSAIDS, but may be useful in women who are at high risk for NSAID-related gastroduodenal toxicity. However, most of these agents have either been withdrawn from the market or issued with black box warnings regarding the risk of serious adverse events. Given these risks and the availability of safe and effective alternatives (nonspecific NSAIDs, as discussed above), we do not use COX-2 inhibitors for treatment of primary dysmenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30993152\">",
"    <span class=\"h3\">",
"     Negative effect on ovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because prostaglandins play an important role in ovulation, NSAIDs, particularly COX-2 inhibitors, can prevent or delay this process [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In fact, the negative effect of COX-2 inhibitors on ovulation is the basis of studies of these agents as potential emergency contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/26\">",
"     26",
"    </a>",
"    ]. Clinical studies examining the effects of various NSAIDs in normally cycling subjects have demonstrated mixed effects on ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women taking NSAIDs and attempting to conceive can generally be reassured because these agents are only used at the time of menstruation. However, if a woman experiences difficulty conceiving, we suggest avoiding these drugs or reducing the dose, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hormonal contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an estrogen-progestin hormonal contraceptive as first line treatment of women with dysmenorrhea who also need contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15853619\">",
"    <span class=\"h3\">",
"     Estrogen-progestin methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen-progestin contraceptives contain potent synthetic progestins, which suppress ovulation and cause the endometrium to become thin over time. The thin endometrium contains relatively small amounts of arachidonic acid, the substrate for most prostaglandin synthesis. As a result of these changes in the endometrium, estrogen-progestin contraceptives reduce both menstrual flow and uterine contractions at menses, thereby decreasing dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15854052\">",
"    <span class=\"h4\">",
"     Pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials of estrogen-progestin contraceptive pills for treatment of primary dysmenorrhea reported a significant benefit of treatment (pooled OR of 2.99, 95% CI 1.76-5.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/34\">",
"     34",
"    </a>",
"    ]. Few trials compared different doses of estrogen and different progestins for treatment of primary dysmenorrhea; the review concluded pain relief was similar for low (&le;35 mcg) and medium (&gt;35 mcg) estrogen doses and there was no clear difference in efficacy among the different pill preparations. A single trial reported third generation progestins (desogestrel and gestodene) were more effective than first- and second-generation progestins (norgestrel,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    , norethisterone [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    in the United States]).",
"   </p>",
"   <p>",
"    Limitations of these data were the small number of comparative trials, the small number of patients in these trials, and the lack of trials evaluating very low estrogen doses (20 mcg) found in modern pills or a wider variety of progestins. However, additional data from observational studies and other randomized trials have demonstrated efficacy of very low dose estrogen pills for treatment of dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. Taken together, these findings suggest that any oral contraceptive pill is likely to be effective.",
"   </p>",
"   <p>",
"    Oral contraceptive pills can be given in monthly or extended cycles, or continuously. In randomized trials, extended or continuous administration provided better relief of menstrual symptoms than cyclic administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link&amp;anchor=H10#H10\">",
"     \"Hormonal contraception for suppression of menstruation\", section on 'Extended and continuous use of contraceptive pills'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women for whom use of a conventional 21 days of",
"    <span class=\"nowrap\">",
"     medication/7",
"    </span>",
"    days of placebo oral contraceptive formulation does not provide sufficient relief of dysmenorrhea, it is reasonable to change to a formulation with a reduced hormone-free-interval (eg, a",
"    <span class=\"nowrap\">",
"     24/4",
"    </span>",
"    formulation) or an extended cycle formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15853661\">",
"    <span class=\"h4\">",
"     Transdermal patch, vaginal ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal and vaginal ring estrogen-progestin contraception are relatively new, thus few trials have evaluated their efficacy for treatment of primary dysmenorrhea or compared them to other therapies. The endometrial effects of estrogen-progestin contraceptives are similar regardless of the method of delivery; therefore, the route of administration should not significantly affect efficacy.",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ring versus pill &mdash; A review of 12 randomized trials comparing the contraceptive vaginal ring with oral contraception concluded both methods had a similar favorable impact on dysmenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/42\">",
"       42",
"      </a>",
"      ]. Among ring users, the proportion of participants reporting moderate or severe dysmenorrhea decreased from 17.4 percent (baseline prevalence) to 5.9 percent; among oral contraception users, dysmenorrhea decreased from 19 percent (baseline prevalence) to 6.4 percent.",
"     </li>",
"     <li>",
"      Patch versus pill &mdash; In a randomized trial designed to evaluate contraceptive efficacy and cycle control in contraceptive patch and oral contraceptive users, dysmenorrhea was slightly more common among women assigned to the patch (13.3 versus 9.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/43\">",
"       43",
"      </a>",
"      ]. Although statistically significant (P 0.04), this may have been due to chance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15853989\">",
"    <span class=\"h3\">",
"     Progestin-only methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the progestin component of estrogen-progestin contraceptives induces the endometrial atrophy that leads to relief of dysmenorrhea, progestin-only contraceptives may be an effective treatment, but have not been studied as extensively as estrogen-progestin contraceptives. Some side-effects, particularly breakthrough bleeding, are more common with progestin-only methods than with estrogen-progestin contraceptives. An advantage of progestin-only contraceptives is that they can be safely used by women for whom contraceptive doses of estrogen are contraindicated (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .) A disadvantage is that they do not inhibit ovulation as well as estrogen-progestin contraception, which may be important when used for treatment of dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15853669\">",
"    <span class=\"h4\">",
"     Injectable contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of depot medroxyprogesterone (DMPA), a long-acting progestin-only injectable contraceptive, users become amenorrheic after one year of use due to endometrial atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/44\">",
"     44",
"    </a>",
"    ]. This makes DMPA a useful treatment option for women with dysmenorrhea. However, return of fertility may be delayed after discontinuation, so women who may want to become pregnant within the next one or two years should choose a different method. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trial in DMPA users has evaluated relief of dysmenorrhea as a primary outcome. A small observational study including 36 adolescent DMPA users reported that two-thirds experienced a reduction in dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/45\">",
"     45",
"    </a>",
"    ]. This observation is consistent with our clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Intrauterine contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reviews of randomized trials and controlled studies with data on non-contraceptive outcomes in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine device (LNG-IUD) users report a reduction in dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In a randomized trial, the LNG-IUD was as effective as depot-GnRH-analogue for control of pelvic pain in women with endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/48\">",
"     48",
"    </a>",
"    ]. A noncomparative study of 29 symptomatic women with magnetic resonance imaging-diagnosed adenomyosis found that placement of a LNG-IUD significantly reduced pain scores at three and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/49\">",
"     49",
"    </a>",
"    ]. Our personal clinical experience also supports the efficacy of the LNG-IUD for treatment of primary dysmenorrhea. Nulliparity is not a contraindication to IUD placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H23833362#H23833362\">",
"     \"Overview of intrauterine contraception\", section on 'Candidates for intrauterine contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An experimental frameless IUD that releases 14 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    daily has also been reported to be effective for treatment of dysmenorrhea, and reduces menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/50\">",
"     50",
"    </a>",
"    ]. The absence of a frame makes this IUD easier to insert and better tolerated in nulliparous women.",
"   </p>",
"   <p>",
"    In contrast, copper T380A IUD users experience increased dysmenorrhea, which is a leading cause of discontinuation during the first year of use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15853705\">",
"    <span class=\"h4\">",
"     Implantable contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large three-year Chilean clinical trial assessing the safety and efficacy of the single-rod etonogestrel-releasing contraceptive, over three quarters of participants who reported primary dysmenorrhea at baseline noted an improvement at the end of treatment, while only 4 percent reported new or worsened dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/51\">",
"     51",
"    </a>",
"    ]. In another trial, the single-rod etonogestrel-releasing contraceptive was associated with a 68 percent reduction of dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia in women with histologically proven endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tocolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary dysmenorrhea is caused by excessive uterine muscle contractions. Thus, agents that block uterine contractility (ie, tocolytics) may be effective in the treatment of this disorder. Nitric oxide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , and calcium channel blockers all have tocolytic effects and are under investigation as potential therapies of dysmenorrhea. We do not use any of these drugs for treatment of primary dysmenorrhea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Glyceryl trinitrate",
"      </strong>",
"      &mdash; A multi-national, double-blind, placebo-controlled, randomized cross-over trial demonstrated that glyceryl trinitrate patches (0.1 mg per hour) were effective for reduction of dysmenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/53\">",
"       53",
"      </a>",
"      ]. However, in another trial that compared glyceryl trinitrate to a NSAID (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      50 mg daily) in the treatment of primary dysmenorrhea, glyceryl trinitrate was less effective than the NSAID and was associated with more side effects, particularly headache [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/54\">",
"       54",
"      </a>",
"      ]. Although glyceryl trinitrate is effective in reducing pain, low tolerability limits its use [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      &mdash; Nifedipine (single oral dose of 20 to 40 mg) has been documented to reduce the intensity of uterine contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/56\">",
"       56",
"      </a>",
"      ] and relieve pain in women with primary dysmenorrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/56-58\">",
"       56-58",
"      </a>",
"      ]. In one study including 12 women with severe dysmenorrhea, nifedipine (single oral dose of 30 mg) relieved dysmenorrhea within 60 minutes in the majority of women treated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/57\">",
"       57",
"      </a>",
"      ]. In another study, nifedipine given to 40 women with dysmenorrhea resulted in moderate to good pain reduction in 36 patients, but was associated with a moderate rate of side effects (facial flushing, tachycardia, headache) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/58\">",
"       58",
"      </a>",
"      ]. Serious cardiovascular events have occurred when short-acting calcium channel blockers were given to women with hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"       \"Major side effects and safety of calcium channel blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Magnesium",
"      </strong>",
"      &mdash; Three small randomized trials found that magnesium was more effective than placebo for relief of dysmenorrhea and was well-tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/13\">",
"       13",
"      </a>",
"      ]. However, the small size of the trials, high drop-out rates, and varying designs precluded a definite recommendation for use of magnesium or the optimum dose or regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY OR ALTERNATIVE MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from controlled trials to support the use of complementary or alternative medicine for treatment of dysmenorrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H829020\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many studies of acupuncture for treatment of dysmenorrhea have been published, these studies were generally of low quality and varied widely in design. In a systematic review including three trials that compared acupuncture to sham acupuncture, all three trials observed a reduction in pain in both groups, but only one trial noted greater pain reduction in the real versus the sham acupuncture group [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/59\">",
"     59",
"    </a>",
"    ]. There need to be more data from controlled trials demonstrating safety and efficacy before these modalities can be recommended.",
"   </p>",
"   <p>",
"    Acupressure has also been reported to be effective, but the available data are limited to small trials of low methodologic quality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H832292\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of four trials of high velocity, low amplitude spinal manipulation reported the technique was no more effective than sham manipulation for the treatment of primary dysmenorrhea, although it was possibly more effective than no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small trial reported Japanese herbal combinations were more effective for reducing pain than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/13\">",
"     13",
"    </a>",
"    ]. In a systematic review of 39 randomized trials of Chinese herbal medicine for treatment of primary dysmenorrhea, this approach appeared to be promising compared to other therapies, but no firm conclusions could be made due to poor methodologic quality of the available trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have had dysmenorrhea refractory to treatment for six months are considered to have chronic pelvic pain. Transcutaneous electrical nerve stimulation (TENS) is a reasonable option for these women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link\">",
"     \"Treatment of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis including three trials (n = 124 women) evaluating high frequency TENS for treatment of dysmenorrhea, TENS was more effective than placebo TENS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/63\">",
"     63",
"    </a>",
"    ]. This modality appears to be a useful alternative in women who cannot or prefer not to use drugs. The degree of pain relief obtained with TENS alone is less than that from drugs; however, some women may be able to lower their analgesic dose with combined therapy.",
"   </p>",
"   <p>",
"    TENS is hypothesized to have two effects: (1) it raises the threshold for pain signals from uterine hypoxia and hypercontractility by sending a volley of afferent impulses through the large diameter sensory fibers of the same nerve root, resulting in lower perception of painful uterine signals, and (2) it stimulates release of endorphins from the peripheral nerves and the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/64\">",
"     64",
"    </a>",
"    ]. Intrauterine pressure studies indicate that TENS therapy had no effect on uterine contractile activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H835173\">",
"    <span class=\"h1\">",
"     SURGICAL INTERRUPTION OF PELVIC NERVE PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nerve transection procedures, including presacral neurectomy, for relief of severe chronic pelvic pain is discussed in detail elsewhere. There is insufficient evidence to recommend these procedures for treatment of dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of chronic pelvic pain in women\", section on 'Nerve transection procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of chronic pelvic pain in women\", section on 'Sacral nerve root neuromodulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF TREATMENT FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women will not obtain adequate pain relief after several months of NSAIDs and hormonal contraception. The prevalence of occult pelvic pathology is high in these women. For example, endometriosis is diagnosed in 12 to 32 percent of women of reproductive age undergoing laparoscopy to determine the cause of pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/67\">",
"     67",
"    </a>",
"    ]. In another study of 100 women with pelvic pain and clinically suspected endometriosis who did not have adequate pain relief with NSAIDs (some also treated with oral contraceptives) after six months, approximately 80 percent were documented to have endometriosis at laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the high likelihood of a pelvic disease being present, we suggest diagnostic laparoscopy for women with dysmenorrhea who have not had adequate relief after three months of NSAIDs and hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the role and timing of laparoscopy should depend on patient and clinician preference. If the woman has used estrogen-progestin contraceptives for three standard cycles without adequate relief, it is reasonable to try alternative hormonal approaches, including continuous estrogen-progestin contraceptives or a long-acting progestin-only method (see",
"    <a class=\"local\" href=\"#H15853989\">",
"     'Progestin-only methods'",
"    </a>",
"    above). Although each of these strategies can be effective in treating pain following surgery for endometriosis, there are little data regarding their use in the treatment of primary dysmenorrhea. Another option is to make a presumptive diagnosis of endometriosis and offer these women treatment with a gonadotropin-releasing hormone (GnRH) agonist analogue, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    (200 mcg intranasal spray twice per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate depot (3.75 mg intramuscularly every four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28233/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the treatment of endometriosis\", section on 'GnRH agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally base treatment decisions on the findings at laparoscopy. If laparoscopy is negative, and the patient has previously failed both hormonal contraception and NSAIDs, we would try a three-month course of a GnRH analogue, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    , since endometriosis may have been missed. Even in the hands of experienced laparoscopists, an accurate diagnosis of endometriosis can be difficult since the disease is often microscopic and presents visually with a variety of atypical lesions. Alternatively, and if not already tried, continuous estrogen-progestin contraception, the LNG-IUD or DMPA can be used in this setting. These contraceptives are more affordable and safer over long-term use than GnRH analogues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"       \"Patient information: Painful periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=see_link\">",
"       \"Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of treatment is to provide adequate relief of pain. Women with a typical clinical history of primary dysmenorrhea can be treated empirically. Nonsteroidal antiinflammatory agents and hormonal contraceptives are the mainstays of therapy. There is no evidence favoring one of these classes of drugs over the other. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who choose to use standard analgesic medications for treatment of dysmenorrhea, we suggest nonsteroidal antiinflammatory drugs (NSAIDs) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      for first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We start with a phenylproprionic acid derivative, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , at the upper end of the dose range (400 to 800 mg orally every six hours). If this does not result in adequate pain relief, we switch to a fenamate, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"       mefenamic acid",
"      </a>",
"      (500 mg loading dose, 250 mg every six hours for three days). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonsteroidal antiinflammatory agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who choose hormonal contraception for treatment of dysmenorrhea, both estrogen-progestin and progestin-only methods are effective. The choice of method should depend upon patient preferences. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hormonal contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment with one of the above modalities fails (ie, NSAIDS or hormonal contraception) after three months, we try a course of treatment with the other modality. Treatment with both hormonal contraceptives and NSAIDs may be effective in women who remain symptomatic on either drug alone. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Application of heat to the lower abdomen is effective in reducing dysmenorrhea. Most women find this method more cumbersome than drug therapy, but it has no side effects. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Heat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with dysmenorrhea who do not respond to three cycles of NSAIDs and hormonal contraception may have a gynecologic disease, such as endometriosis, causing their pain. We perform diagnostic laparoscopy on these patients, and base subsequent treatment decisions on findings at laparoscopy. Alternatively, one can make a clinical diagnosis of endometriosis and offer these women medical treatment with a gonadotropin-releasing hormone (GnRH) agonist analogue, continuous estrogen-progestin contraception, the LNG-IUS, or DMPA. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management of treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/1\">",
"      Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol 2001; 97:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/2\">",
"      Akin M, Price W, Rodriguez G Jr, et al. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. J Reprod Med 2004; 49:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/3\">",
"      Israel RG, Sutton M, O'Brien KF. Effects of aerobic training on primary dysmenorrhea symptomatology in college females. J Am Coll Health 1985; 33:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/4\">",
"      Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD004142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/5\">",
"      Golomb LM, Solidum AA, Warren MP. Primary dysmenorrhea and physical activity. Med Sci Sports Exerc 1998; 30:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/6\">",
"      Rakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: a randomized clinical trial. J Pediatr Adolesc Gynecol 2011; 24:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/7\">",
"      Hatcher RA. Counseling couples about coitus during menstrual flow. Contracept Technol Update 1981; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/8\">",
"      Proctor ML, Murphy PA, Pattison HM, et al. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD002248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/9\">",
"      Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet Gynecol 2000; 95:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/10\">",
"      Abdul-Razzak KK, Ayoub NM, Abu-Taleb AA, Obeidat BA. Influence of dietary intake of dairy products on dysmenorrhea. J Obstet Gynaecol Res 2010; 36:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/11\">",
"      Ziaei S, Faghihzadeh S, Sohrabvand F, et al. A randomised placebo-controlled trial to determine the effect of vitamin E in treatment of primary dysmenorrhoea. BJOG 2001; 108:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/12\">",
"      Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG 2005; 112:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/13\">",
"      Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2001; :CD002124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/14\">",
"      Lasco A, Catalano A, Benvenga S. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study. Arch Intern Med 2012; 172:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/15\">",
"      Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/16\">",
"      Fedele L, Marchini M, Acaia B, et al. Dynamics and significance of placebo response in primary dysmenorrhea. Pain 1989; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/17\">",
"      Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD001751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/18\">",
"      Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 1984; 148:96.",
"     </a>",
"    </li>",
"    <li>",
"     Zhang, WY, Li Wan, Po A. Efficacy of minor analgesics in primary dysmenorrhea: a systematic review. Br J Obstet Gynaecol 1998; 105;780.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/20\">",
"      Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010; 81:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/21\">",
"      Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA 1979; 241:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/22\">",
"      Milsom I, Minic M, Dawood MY, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther 2002; 24:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/23\">",
"      Pall M, Frid&eacute;n BE, Br&auml;nnstr&ouml;m M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/24\">",
"      Duffy DM, VandeVoort CA. Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor. Fertil Steril 2011; 95:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/25\">",
"      Bata MS, Al-Ramahi M, Salhab AS, et al. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol 2006; 46:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/26\">",
"      Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Hum Reprod 2010; 25:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/27\">",
"      Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril 2001; 76:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/28\">",
"      Toppozada, M, El-Abd, M, El-Sokkary, H, El-Rahman, HA. Effect of a prostaglandin inhibitor of human ovulation. Singapore J Obstet Gynecol 1979; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/29\">",
"      Lundstr&ouml;m V, Landgren BM, Eneroth P, Johannisson E. The effect of a prostaglandin synthetase inhibitor on the hormonal profile and the endometrium in women. Acta Obstet Gynecol Scand Suppl 1983; 113:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/30\">",
"      Athanasiou S, Bourne TH, Khalid A, et al. Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women. Fertil Steril 1996; 65:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/31\">",
"      Killick S, Elstein M. Pharmacologic production of luteinized unruptured follicles by prostaglandin synthetase inhibitors. Fertil Steril 1987; 47:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/32\">",
"      Norman RJ. Reproductive consequences of COX-2 inhibition. Lancet 2001; 358:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/33\">",
"      Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril 2004; 81:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/34\">",
"      Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; :CD002120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/35\">",
"      Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005; 106:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/36\">",
"      Callejo J, D&iacute;az J, Ruiz A, Garc&iacute;a RM. Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea. Contraception 2003; 68:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/37\">",
"      Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/38\">",
"      Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/39\">",
"      Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/40\">",
"      Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; :CD004695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/41\">",
"      Machado RB, de Melo NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. Contraception 2010; 81:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/42\">",
"      Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/43\">",
"      Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/44\">",
"      Hubacher D, Lopez L, Steiner MJ, Dorflinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 2009; 80:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/45\">",
"      Harel Z, Biro FM, Kollar LM. Depo-Provera in adolescents: effects of early second injection or prior oral contraception. J Adolesc Health 1995; 16:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/46\">",
"      Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/47\">",
"      Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007; 75:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/48\">",
"      Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/49\">",
"      Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/50\">",
"      Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/51\">",
"      Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5 Suppl 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/52\">",
"      Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/53\">",
"      Moya RA, Moisa CF, Morales F, et al. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet 2000; 69:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/54\">",
"      Facchinetti F, Sgarbi L, Piccinini F, Volpe A. A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial. Gynecol Endocrinol 2002; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/55\">",
"      Morgan PJ, Kung R, Tarshis J. Nitroglycerin as a uterine relaxant: a systematic review. J Obstet Gynaecol Can 2002; 24:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/56\">",
"      Andersson KE, Ulmsten U. Effects of nifedipine on myometrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol 1978; 85:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/57\">",
"      Ulmsten U. Calcium blockade as a rapid pharmacological test to evaluate primary dysmenorrhea. Gynecol Obstet Invest 1985; 20:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/58\">",
"      Sandahl B, Ulmsten U, Andersson KE. Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea. Arch Gynecol 1979; 227:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/59\">",
"      Cho SH, Hwang EW. Acupuncture for primary dysmenorrhoea: a systematic review. BJOG 2010; 117:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/60\">",
"      Cho SH, Hwang EW. Acupressure for primary dysmenorrhoea: a systematic review. Complement Ther Med 2010; 18:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/61\">",
"      Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2006; :CD002119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/62\">",
"      Zhu X, Proctor M, Bensoussan A, et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2007; :CD005288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/63\">",
"      Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev 2002; :CD002123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/64\">",
"      Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/65\">",
"      Smith RP, Heltzel JA. Interrelation of analgesia and uterine activity in women with primary dysmenorrhea. A preliminary report. J Reprod Med 1991; 36:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/66\">",
"      Proctor ML, Latthe PM, Farquhar CM, et al. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2005; :CD001896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/67\">",
"      Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28233/abstract/68\">",
"      Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Practice Bulletin Number 11. Medical Management of Endometriosis. December 1999.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5414 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28233=[""].join("\n");
var outline_f27_36_28233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28816153\">",
"      Goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28816178\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SELF-CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H832071\">",
"      Exercise and sexual activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H832078\">",
"      Behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diet and vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonsteroidal antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30993152\">",
"      - Negative effect on ovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15853619\">",
"      - Estrogen-progestin methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15854052\">",
"      Pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15853661\">",
"      Transdermal patch, vaginal ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15853989\">",
"      - Progestin-only methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15853669\">",
"      Injectable contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15853705\">",
"      Implantable contraception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tocolytics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLEMENTARY OR ALTERNATIVE MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H829020\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H832292\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H835173\">",
"      SURGICAL INTERRUPTION OF PELVIC NERVE PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT OF TREATMENT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/16/22795\" title=\"table 1\">",
"      Scoring system for dysmenorrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/52/29516\" title=\"table 2\">",
"      NSAID dose for medical therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=related_link\">",
"      Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39879?source=related_link\">",
"      Primary dysmenorrhea in adult women: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28234="Nonsurgical local treatment strategies for colorectal cancer liver metastases";
var content_f27_36_28234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Alan P Venook, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/36/28234/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/36/28234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 142,820 Americans are diagnosed with colon or rectal cancer annually, and 50,830 die from this disease, most with metastatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/1\">",
"     1",
"    </a>",
"    ]. Global, country-specific incidence and mortality rates are available from the World Health Organization",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/\">",
"     GLOBOCAN database",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Hepatic metastatic disease from colorectal cancer (CRC) is a significant clinical problem. The liver is the dominant metastatic site for such patients, and although two-thirds of affected patients have extrahepatic spread, some have disease that is isolated to the liver. For such patients, regional treatment approaches may be considered as an alternative to systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection is the treatment of choice for patients with isolated liver metastases when feasible. For patients with four or fewer isolated hepatic lesions, five year relapse-free survival rates after resection range from 24 to 58 percent, averaging 30 percent (",
"    <a class=\"graphic graphic_table graphicRef74509 \" href=\"UTD.htm?23/60/24524\">",
"     table 1",
"    </a>",
"    ). Many of these patients are potentially cured.",
"   </p>",
"   <p>",
"    The actual percent of patients with isolated hepatic metastases who are amenable to potentially curative resection is a moving target because of evolving technologies that have expanded the pool of patients who can be considered for surgical intervention. However, the majority are not surgical candidates because of tumor size, location, multifocality, or inadequate hepatic reserve.",
"   </p>",
"   <p>",
"    There are several nonsurgical treatment options for patients with liver-isolated colorectal cancer metastases who are not candidates for potentially curative resection. These include systemic chemotherapy, regional chemotherapy via the hepatic artery, selective internal radiation using yttrium-labeled glass or resin microspheres, and regional tumor ablation (hyperthermic or radiofrequency coagulation, intratumoral injection of ethanol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , and cryotherapy).",
"   </p>",
"   <p>",
"    Local or regional treatment approaches may be considered after the cancer has progressed on systemic therapies but remains isolated to the liver or as a means of delaying the need for systemic chemotherapy in patients who have liver-isolated metastatic disease. Whether this rationale is valid or not is unclear. Although these methods (particularly radiofrequency ablation, RFA) can provide local control in a high number of patients, whether there are any long-term survivors (ie, cures) remains uncertain. Moreover, it is unclear whether the sequential use of regional treatments followed by systemic chemotherapy at the time of progression provides better long-term benefit in terms of duration of symptom control or survival than systemic chemotherapy alone.",
"   </p>",
"   <p>",
"    An increasingly utilized option for patients with a good performance status who are operable but technically unresectable is initial systemic chemotherapy with modern combination regimens that include the more active agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , followed by reevaluation for liver resection. At least some patients can be rendered potentially resectable using this approach, although chemotherapy-induced liver toxicity has emerged as a significant issue. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on nonsurgical methods for local tumor ablation, regional chemotherapy into the hepatic artery, and radiation therapy. Resection and the use of pre resection (induction) chemotherapy as well as systemic and regional treatment strategies following resection of liver metastases from colorectal cancer are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOPSY CONFIRMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the clinical picture, biopsy may be indicated to confirm the diagnosis of metastatic disease. However, whether all patients need biopsy confirmation of suspected metastatic disease is debated. Many oncologists feel it is important to provide tissue documentation of the first site of noncurable disease, while others consider that biopsy is not necessary in a patient with a history of colorectal cancer in the preceding five years who has a new elevation of CEA and new unresectable liver lesions on imaging that are clinically suspicious.",
"   </p>",
"   <p>",
"    The risk of tract seeding from percutaneous fine needle aspiration (FNA) biopsy appears small (only a handful of case reports are described in journals listed in MEDLINE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]), although this complication was described in five of 51 cases of biopsy-proven hepatic colorectal metastases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TUMOR ABLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local tumor ablation can be accomplished in many ways. The direct intratumoral instillation of alcohol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    or hyperthermic ablation (using radiofrequency waves or microwaves) has largely replaced cryotherapy as the methods of choice. In general, lesions that are amenable to surgical resection also lend themselves to ablative treatments (one or a few metastases, none greater than 5 cm in diameter). Thus, local ablative methods may be considered a less morbid alternative to surgical resection in patients who are at high risk for or otherwise not candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assessing clinical benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard methods to assess treatment response (eg, unidimensional RECIST criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/10\">",
"     10",
"    </a>",
"    ], bidimensional perpendicular measurement using WHO criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/11\">",
"     11",
"    </a>",
"    ]) involve measurement of tumor dimensions before and after treatment. Methods such as these disregard the extent of necrosis, which is the end result of locoregional ablative therapies.",
"   </p>",
"   <p>",
"    Among patients treated for primary hepatocellular cancer (HCC), the efficacy of percutaneous ablation therapy is assessed by dynamic CT or MRI one month after therapy. The absence of contrast uptake within the tumor is thought to reflect tumor necrosis, while the persistence of contrast uptake indicates persistent disease. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Assessing response to locoregional therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with liver metastases, contrast enhancement is typically absent, and there is no consensus on appropriate endpoints to define clinical benefit from locoregional therapies. Treated tumors characteristically show low density on posttreatment computed tomography (CT) scans. These regions, which are often interpreted as tumor necrosis, are often larger than the area of the original tumor. However, this appearance is nonspecific, and should not be considered to represent an objective response, since it is nonspecific.",
"   </p>",
"   <p>",
"    A reduction in serum levels of tumor markers such as carcinoembryonic antigen (CEA) may not be accompanied by objective tumor shrinkage. However, at least some data suggest a correlation between the magnitude of CEA decline and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of these issues, probably the most important factor in determining benefit is the time to progression for the individual lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperthermic coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermic coagulative necrosis can be accomplished by radiofrequency waves or by lasers or microwaves (mainly outside of the US). As with percutaneous intratumoral injections and cryotherapy, hyperthermic coagulation is limited by the difficulty in determining the true lesion margin, which often extends beyond the leading edge, and the lack of specificity of tissue damage. In contrast to cryosurgery which requires operative intervention, these procedures can be performed percutaneously. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cryotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) has been widely applied to patients with primary hepatocellular cancer and metastatic liver tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link&amp;anchor=H13#H13\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Radiofrequency ablation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RFA can be performed with open, laparoscopic, or percutaneous approaches. Some studies have reported that the approach by which RFA is performed has an impact on tumor recurrence rates, with the fewest local recurrences after open RFA, followed by laparoscopy, and finally percutaneous RFA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. However, local tumor recurrence rates overlap broadly with each technique, and physician experience (as well as the type of RFA equipment) is also inversely related to local recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. An expert panel convened by the American Society of Clinical Oncology (ASCO) to review the evidence on RFA for colorectal cancer liver metastases concluded that there is insufficient evidence to resolve the issue of optimal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of the tumors within the liver also impacts on the success of RFA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions that are located near large (&ge;1 cm) blood vessels may be inadequately treated because of the heat sink effect of rapid blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Percutaneous RFA may sometimes be avoided for treatment of lesions that are located in the dome or along the inferior liver edge for fear of diaphragmatic injury [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/23\">",
"       23",
"      </a>",
"      ] or intestinal perforation. However, with attention to technique (such as insulating adjacent bowel from the thermal process, an approach that can be accomplished using a laparoscopic or open laparotomy approach), these lesions can be successfully treated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/24\">",
"       24",
"      </a>",
"      ]. Tumors at the inferior edge of the liver should not be treated percutaneously (and instead by a laparoscopic or open approach) if the stomach, duodenum, or transverse colon lies in close proximity to the tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vast majority of published data on efficacy of RFA for colorectal cancer liver metastases come from retrospective series many of which have limited follow-up (20 months or less); there are few published randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/13,25-30\">",
"     13,25-30",
"    </a>",
"    ]. A systematic review of the literature on RFA for colorectal cancer liver metastases reported a wide range of five-year survival (14 to 55 percent), and local recurrence rates (3.6 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"     19",
"    </a>",
"    ]. However, both the retrospective series and limited number of prospective trials consist of a variable mix of patients with potentially resectable liver-isolated disease, and unresectable liver metastases with or without extrahepatic disease involvement. Finally, few series provide data on the use of chemotherapy concurrent with or following RFA. Some papers report tumor outcomes while others report patient outcomes. End points have not always been reported in the same way, and survival or recurrence was sometimes reported from diagnosis of metastatic colorectal cancer or from the first or subsequent RFA procedure. All of these issues compromise the assessment of long-term outcomes from RFA.",
"   </p>",
"   <p>",
"    Among patients with potentially resectable liver metastases, whether the results with RFA are as good as can be achieved with surgical resection with or without postresection chemotherapy remains an open question. There are no randomized trials. Many retrospective comparative series suggest lower local recurrence rates, and better progression-free survival, and in some cases, better overall survival, after resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. However, retrospective comparisons such as these cannot be used to ascertain the superiority of resection over RFA because patients treated with resection alone versus RFA differ across several important clinical, pathologic, and treatment-related variables [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/37\">",
"     37",
"    </a>",
"    ]. Definitive conclusions cannot be made in the absence of randomized trials directly comparing both approaches.",
"   </p>",
"   <p>",
"    Nevertheless, given the evidence from retrospective reports that resection improves overall survival, particularly in the absence of extrahepatic disease, a systematic review of the literature by an expert panel from ASCO concluded that there is not enough evidence to support the use of RFA over resection in patients with potentially resectable colorectal cancer liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"     19",
"    </a>",
"    ]. A similar conclusion was reached in a 2012 Cochrane review [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RFA is sometimes applied intraoperatively following incomplete resection in patients with isolated liver metastases from CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/32,39-42\">",
"     32,39-42",
"    </a>",
"    ], and in those with extrahepatic disease involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the benefits of RFA in these settings (as compared to systemic chemotherapy alone) remain unproven.",
"   </p>",
"   <p>",
"    There is no evidence to support a survival or quality of life benefit to ablating liver metastases in the presence of extrahepatic disease. One team of investigators reported their 10-year experience in 234 consecutive patients with colorectal cancer liver metastases who were not candidates for resection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failed chemotherapy, and underwent laparoscopic RFA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/28\">",
"     28",
"    </a>",
"    ]. Fifty-five (24 percent) had extrahepatic disease at the time of RFA, which was not specifically treated. The median survival for all patients after RFA was 24 months, and the actual three- and five-year survival rates were 20 and 18 percent, respectively. Survival was not worse among patients with extrahepatic disease involvement.",
"   </p>",
"   <p>",
"    However, this appears to be the only published report that notes no difference in survival for patients with versus without extrahepatic disease involvement. Although data on the use of post RFA chemotherapy were not provided, it is likely that at least some of the prolonged survival was attributable to salvage chemotherapy, since the median progression-free survival for the patients undergoing RFA who had no overt extrahepatic disease was only six months. The ASCO expert panel concluded that there is not enough evidence to justify the use of RFA in patients with viable extrahepatic disease and those with unresectable liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"     19",
"    </a>",
"    ]. This latter position is supported by a later randomized phase II trial in which 119 patients with non-resectable isolated colorectal cancer liver metastases (85 percent previously untreated) were randomly assigned to chemotherapy (85 percent FOLFOX with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) with or without RFA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/29\">",
"     29",
"    </a>",
"    ]. Although patients who received combined therapy had a higher three-year progression-free survival rate (28 versus 11 percent), overall survival, the primary endpoint, was not significantly improved (30 months survival 62 versus 58 percent).",
"   </p>",
"   <p>",
"    RFA is a relatively well-tolerated technique; however, severe and potentially fatal complications can arise. In the ASCO systematic review, the reported mortality rate was 0 to 2 percent, and the major complication rate was between 6 and 9 percent in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest series to address complications included 312 patients with hepatic tumors (predominantly colorectal metastases) who underwent 350 procedures (226 percutaneous and the remainder intraoperative) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/43\">",
"     43",
"    </a>",
"    ]. Five deaths were attributed to treatment (one each from liver failure and colon perforation, three from portal vein thrombosis). Portal vein thrombosis was significantly more common in cirrhotic",
"    <span class=\"nowrap\">",
"     (2/5)",
"    </span>",
"    compared to noncirrhotic livers",
"    <span class=\"nowrap\">",
"     (0/54)",
"    </span>",
"    after intraoperative RFA performed during a Pringle maneuver. There were 37 nonfatal serious complications (incidence 10.6 percent), which included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver abscess in seven, which developed in all three patients with a bilioenteric anastomosis compared with less than 2 percent of the others",
"     </li>",
"     <li>",
"      Pleural effusion and skin burns in five patients each",
"     </li>",
"     <li>",
"      Hypoxemia during treatment in four patients",
"     </li>",
"     <li>",
"      Pneumothorax in three patients",
"     </li>",
"     <li>",
"      Subcapsular hematoma in two patients",
"     </li>",
"     <li>",
"      Acute renal insufficiency, hemoperitoneum, and needle tract seeding in one patient each",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the place of RFA in the management of colorectal cancer liver metastases remains uncertain, particularly in patients who have extrahepatic disease involvement. It is a potential option for patients with potentially resectable isolated liver metastases who are not surgical candidates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Microwave hyperthermia and interstitial laser ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microwave hyperthermia can cut liver and prevent bleeding from this cut edge by coagulating the cut end simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Although best studied for treatment of small hepatocellular cancers, microwave hyperthermia is beginning to be used for metastatic liver tumors, although the experience is predominantly (but not exclusively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/46\">",
"     46",
"    </a>",
"    ]) from Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the only randomized trials directly comparing methods for local nonsurgical ablation, 30 patients with potentially resectable hepatic metastases from CRC were randomly assigned to laparotomy with ultrasonographically-guided microwave coagulation or surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/44\">",
"     44",
"    </a>",
"    ]. Both approaches were associated with similar two-year (56 and 57 percent) and three-year (14 and 23 percent) survival rates, as well as similar median survival (27 and 25 months, respectively).",
"   </p>",
"   <p>",
"    Published experience with interstitial laser thermotherapy is limited to a few institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. The largest series consisted of 603 patients who underwent MRI-guided laser thermotherapy of 1801 colorectal cancer liver metastases; details of additional oncologic therapy were not provided [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/51\">",
"     51",
"    </a>",
"    ]. Clinically relevant complications included pleural effusion (1.1 percent), liver abscess (0.4 percent), and intraabdominal bleeding, pneumothorax, bile duct injury, bronchobiliary fistula, and death within 30 days in 0.1 percent each. At six months postprocedure, 95 percent of the lesions were controlled locally, and none recurred thereafter with up to 7.6 years of follow-up; median follow-up duration was not stated. Five-year survival was 37 percent.",
"   </p>",
"   <p>",
"    Neither of these techniques is widely available, and proof of their superiority over surgical resection will require randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25786933\">",
"    <span class=\"h2\">",
"     Percutaneous ethanol or acetic acid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous injection techniques have been most widely applied to small hepatocellular cancers (HCCs). Although widely used, particularly in Japan, intratumoral injections are limited by the inability to access some lesions percutaneously, difficulty in adequately ablating all regions of the tumor, especially at the leading edge, and the lack of consensus on appropriate end points to determine clinical benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=see_link&amp;anchor=H950876074#H950876074\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Percutaneous ethanol injection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologies other than HCC do not respond as well to percutaneous injection of ethanol. This is perhaps because of difficulties in achieving equal distribution throughout the metastatic lesion, and because in HCC (as opposed to CRC metastases), the capsule around the tumor and the cirrhotic liver prevent dissemination of the ethanol into normal surrounding liver tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In fact, a consensus workshop in 1992 concluded that alcohol injection was not an appropriate therapy for liver metastases from CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/55\">",
"     55",
"    </a>",
"    ]. Percutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    injection has not been adequately studied for CRC liver metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the availability of newer and safer modalities, cryotherapy is rarely used in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary: Local ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with isolated liver metastases from colorectal cancer who are not amenable to potentially curative resection because of tumor size, location, multifocality, or inadequate hepatic reserve, local methods of tumor ablation provide an alternative to systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .) Radiofrequency ablation (RFA) can be administered as an outpatient procedure and is the preferred procedure.",
"   </p>",
"   <p>",
"    The best results with RFA are in patients with three or fewer lesions that are 3.5 cm or less in diameter that are not located near major vascular structures. These are the same patients for whom surgical resection is often considered, and an important unresolved issue is whether long-term outcomes with RFA are as favorable as with resection. At present, resection is the preferred approach, if feasible. Another approach that can be considered for selected patients with initially unresectable disease is systemic chemotherapy followed by reevaluation for resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of RFA for regional treatment of liver metastases in patients with extrahepatic disease who are undergoing systemic chemotherapy remains uncertain and this approach should not be considered standard at present. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiofrequency ablation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEPATIC INTRAARTERIAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional chemotherapy through the hepatic artery is a therapeutic option for patients with isolated liver metastases that are not amenable to surgical resection or local ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic intraarterial (HIA) chemotherapy is based upon the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver macrometastases (&gt;0.5 cm) derive more than 80 percent of their blood supply from the hepatic arterial circulation, while normal hepatocytes are supplied primarily by the portal circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/56\">",
"       56",
"      </a>",
"      ]. As a result, the administration of chemotherapy into the hepatic artery allows the selective delivery of drug to the tumor with relative sparing of normal hepatocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depending upon a drug's clearance and toxicity profile, a marked increase in the local concentration of drug may be achieved by injection into the hepatic artery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/57\">",
"       57",
"      </a>",
"      ]. Regional administration of drugs that are rapidly metabolized in the liver by a first-pass effect leads to higher levels of drug exposure and minimizes systemic side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152022\">",
"    <span class=\"h2\">",
"     Transarterial chemoembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transarterial chemoembolization (TACE), as is used for unresectable hepatocellular cancer, has been investigated in patients with colorectal cancer liver metastases, using both conventional techniques and drug eluting beads. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=see_link&amp;anchor=H1248650293#H1248650293\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Transarterial embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited experience suggests that TACE can achieve disease stabilization in 40 to 60 percent of treated patients, but whether this translates into a prolongation of survival relative to systemic chemotherapy alone is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/58-66\">",
"     58-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survival advantage for hepatic intraarterial (HIA) infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -loaded drug eluting beads (DEBIRI) compared to systemic chemotherapy was suggested in a small phase III trial in which 74 patients with isolated hepatic metastases from CRC were randomly assigned to two monthly infusions of HIA DEBIRI or four months of IV therapy with FOLFIRI (irinotecan plus short term infusional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/66\">",
"     66",
"    </a>",
"    ]. All patients had received at least two or three lines of prior chemotherapy. The DEBIRI group had a significantly higher objective response rate (69 versus 20 percent), overall survival (56 versus 32 percent at two years, median 22 versus 15 months), and progression-free survival (7 versus 4 months). While the median time to hepatic progression was significantly longer in the group treated with HIA DEBIRI (7 versus 4 months), the median time to extrahepatic progression was also inexplicably longer in this group (median 13 versus 9 months).",
"   </p>",
"   <p>",
"    Larger randomized trials are needed to confirm these results before it can be concluded that HIA therapy provides superior outcomes to standard systemic chemotherapy. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3152043\">",
"    <span class=\"h2\">",
"     HIA chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most series of colorectal liver metastases have studied infusional HIA chemotherapy without embolization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Early phase III trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive clinical investigation of HIA chemotherapy began in the 1970s and 1980s, initially via percutaneously placed catheters and then by a totally implantable pump system, which made this an ambulatory treatment.",
"   </p>",
"   <p>",
"    Multiple major prospective trials, enrolling over 400 previously untreated patients with metastatic CRC, randomly assigned patients to systemic fluoropyrimidine chemotherapy or to HIA FUDR (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    ) delivered via an implanted pump [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Although in each study, the response rate to HIA chemotherapy was superior to systemic treatment, this did not translate into a significant survival improvement in any study, or in two separate meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Subsequent improvements in HIA technique of pump placement and methods of optimizing pump chemotherapy led to a resurgence of interest in the use of HIA therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Technique and complications of HIA pump placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of intrahepatic artery catheter placement is to enable bilobar hepatic perfusion of chemotherapy and prevent administration to the stomach or duodenum (misperfusion).",
"   </p>",
"   <p>",
"    A preoperative angiogram is performed to define the arterial supply of the liver. If the vascular anatomy is suitable for placement of a hepatic artery catheter, exploratory laparotomy is performed, initially to exclude unresectable extrahepatic tumor. If there is no contraindication to pump placement, a cholecystectomy is performed. Total devascularization of the distal stomach and proximal duodenum is performed in order to minimize the risk of misperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/74\">",
"     74",
"    </a>",
"    ]. Any variations in the hepatic lobar arterial supply, including a replaced or accessory left or right hepatic artery, require ligation of that vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nearly all cases, the gastroduodenal artery is the vessel of choice for cannulation. Once the catheter is situated, the pump itself is placed in a subcutaneous pocket and it is loaded with heparinized water. The catheter is passed through the abdominal wall, trimmed to an appropriate length and inserted into the gastroduodenal artery so that its tip is just at the take-off of the gastroduodenal artery. Finally, 5 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    are injected into the pump side port, and the liver, stomach and duodenum are examined with a Woods lamp to verify bilobar liver perfusion and to exclude misperfusion to the stomach or duodenum.",
"   </p>",
"   <p>",
"    Postoperatively, before initiating HIA chemotherapy, a Tc-99m macro-aggregated albumin (TcMAA) scan is necessary to ensure the absence of misperfusion and to assess the adequacy of whole liver perfusion. Perfusion of the entire liver parenchyma is probably important for maximal clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early postoperative complications consist of arterial injury leading to hepatic artery thrombosis, incomplete perfusion of the entire liver due to missed recognition of an accessory hepatic artery, misperfusion to the stomach or duodenum, or pump pocket hematoma. If the above steps are followed rigorously, these complications should occur in fewer than 5 percent of patients. In experienced hands, operative mortality approaches that of an open cholecystectomy.",
"   </p>",
"   <p>",
"    Late complications are more common and include inflammation or ulceration of the stomach or duodenum, pump pocket infection, or catheter thrombosis. The development of antral or duodenal ulceration should prompt endoscopic examination of the stomach and duodenum with concomitant injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    through the pump side-port [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/78\">",
"     78",
"    </a>",
"    ]. Immediate deep blue staining of the ulcerated site warrants an angiographic search for a vessel responsible for the misperfusion. Once identified, the offending vessel can often be embolized using interventional radiological techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Optimizing chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of fluorodeoxyuridine (FUDR) employed in early phase III trials of hepatic intraarterial (HIA) chemotherapy (0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 14 of 28 days) induced severe biliary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/79\">",
"     79",
"    </a>",
"    ]. Biliary sclerosis results either from toxic effects on the biliary system or ischemic changes secondary to fibrosis of the pericholangitic venous plexus, both of which can result in stricture of the bile ducts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H19#H19\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Fluorouracil and capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of strategies have been explored in an attempt to overcome treatment-limiting toxicity and to maximize the safety and efficacy of HIA treatment. The majority of reports have evaluated modifications of 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU)-based therapy, while more recent studies are exploring other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25787209\">",
"    <span class=\"h4\">",
"     5-FU-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to ameliorate any inflammatory aspect of the hepatobiliary toxicity, FUDR (0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 14 days) was administered with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in a randomized phase II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/80\">",
"     80",
"    </a>",
"    ]. While the addition of dexamethasone did not lessen biliary toxicity, both the response rate and median survival were superior to FUDR alone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    enhances the activity of 5-FU by promoting the formation of a stable ternary complex with thymidylate synthetase, thus permitting prolonged inhibition of the enzyme by 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H4#H4\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on '5-FU-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FUDR modulation by intraarterial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was studied in a series of six different regimens by the same investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/81\">",
"     81",
"    </a>",
"    ]. The response rate in previously untreated patients was 78 percent, and the median survival was 25 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/82\">",
"     82",
"    </a>",
"    ]. A strict paradigm for dose-reduction (",
"    <a class=\"graphic graphic_table graphicRef74509 \" href=\"UTD.htm?23/60/24524\">",
"     table 1",
"    </a>",
"    ) reduced the incidence of biliary sclerosis to 3 percent, although dose adjustment or temporary treatment delay was necessary in nearly every patient. The liver was the initial site of failure in two-thirds of the patients. FUdR hepatotoxicity is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H19#H19\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Fluorouracil and capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25787224\">",
"    <span class=\"h4\">",
"     Oxaliplatin and irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the available data are scant, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    can be safely delivered to the liver via the hepatic artery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. In one report, 28 previously untreated patients with liver isolated metastatic CRC received intraarterial oxaliplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours) followed by IV 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    administered according to the de Gramont regimen (leucovorin 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours, followed by 5-FU 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    bolus, and then a 22 hour infusion of 5-FU 600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    with repeated courses every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/83\">",
"     83",
"    </a>",
"    ]. The objective response rate was 64 percent, and the median overall survival was 27 months. Grade 3 or 4 neutropenia complicated therapy in ten patients, and there were two treatment-related deaths, one in the setting of febrile neutropenia.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    by HIA infusion remains investigational at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25787231\">",
"    <span class=\"h4\">",
"     HIA plus systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another method of optimizing chemotherapy is combined use of intraarterial plus systemic chemotherapy. Such an approach would address the concern of extrahepatic tumor progression while achieving maximal therapeutic effect in the liver.",
"   </p>",
"   <p>",
"    At least two trials suggest that systemic 5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    alternating with HIA with FUDR might improve survival in patients with resected isolated hepatic metastases. However, there is no survival benefit from this approach relative to HAI therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/87\">",
"     87",
"    </a>",
"    ], and the systemic chemotherapy arm in all trials (infusional 5-FU and LV-modulated 5-FU) did not include either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , two agents that clearly add benefit to 5-FU and LV in the setting of advanced CRC. Thus, the benefit of this approach compared to modern systemic chemotherapy remains uncertain. This topic is discussed in detail elsewhere, as is the use of systemic therapy following resection of liver metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Therapy after resection of liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recent studies are exploring the combined use of HIA FUDR and systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"     ;",
"    </span>",
"    preliminary results show that such combinations are safe and result in a high rate of response in patients with unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Contemporary randomized trials and meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite optimization of surgical techniques and the chemotherapy regimen, the benefit of HIA chemotherapy remains uncertain.",
"   </p>",
"   <p>",
"    At least three trials comparing HIA therapy with IV",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/89-91\">",
"     89-91",
"    </a>",
"    ] and a meta-analysis of these three trials combined with seven earlier randomized trials in which the control arm was systemic therapy or best supportive care concluded that response rates were higher with HIA than with systemic 5-FU-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/92\">",
"     92",
"    </a>",
"    ]. However, this did not translate into a significant overall survival advantage.",
"   </p>",
"   <p>",
"    None of the trials included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in the control arm. These regimens have been shown to improve survival compared to 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    alone in randomized trials. With these newer approaches to therapy, objective response rates as high as 45 to 50 percent have been achieved, with median survival durations as high as 20 months, which is significantly better than the 12 to 15 month average survivals reported for 5-FU and leucovorin alone. It is unknown whether any HIA approach will improve upon or even match these results. Thus, the relative benefit and indications for HIA chemotherapy in patients with hepatic metastases from CRC remain uncertain, and this approach has fallen out of favor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a multitude of trials, the relative benefit of hepatic intraarterial chemotherapy for patients with hepatic metastases from CRC remains unclear. The outcomes of phase II and phase III trials evaluating HIA chemotherapy in previously untreated patients must be considered in context. The control arm in all of the phase III trials comparing regional versus systemic chemotherapy was intravenous 5-FU with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . The standard approach for newly diagnosed metastatic colorectal cancer is the combination of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus 5-FU and leucovorin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Benchmark responses rates with these newer regimens are 45 to 50 percent, and median survival durations are as high as 20 months (significantly better than the 12 to 15 month average survival with 5-FU and leucovorin alone). It is unknown whether any HIA approach will improve upon or even match these results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If it is used, this approach should be restricted to centers with expertise in the technical aspects of regional chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiation therapy for treatment of hepatic metastases has been limited by low tolerance of the normal liver parenchyma. The maximal acceptable dose to the whole liver is 35 Gy, far below that required to destroy adenocarcinoma metastases (estimated to be 70 Gy or higher). Newer approaches using conformal treatment planning with concurrent intrahepatic artery",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], but experience is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stereotactic radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions. Early experience with stereotactic radiotherapy for liver metastases suggests that this technique is safe and associated with sustained local control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H6#H6\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent implantation of Iodine-125 brachytherapy seeds has been infrequently used in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. While some data suggest that this approach might provide the opportunity for long term local control in patients with incompletely resected hepatic metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/95\">",
"     95",
"    </a>",
"    ], the logistics of placing the seeds intraoperatively are complex. Moreover, whether this approach is superior to intraoperative cryoablation is unclear. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Cryotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative means of delivering focal radiation employs radioactive isotopes (eg, 131-labeled-lipiodol or yttrium-90 [Y90]-tagged glass or resin microspheres) that are delivered selectively to the tumor via the hepatic artery. After injection into the appropriate hepatic artery, the microspheres become preferentially lodged in the arteriolar vasculature surrounding metastatic tumor deposits, delivering high doses of radiation to the area. Maximum tissue penetration for the pure beta-emitter Y90 is 1.1 cm, so most normal liver parenchyma is spared.",
"   </p>",
"   <p>",
"    SIR-Spheres&reg;, a product consisting of 90Y-labeled biocompatible resin microspheres (20 to 40 micrometers in diameter), is available in North America and approved in the United States (concurrent with HIA injection of FUDR) for the treatment of unresectable liver metastases from primary CRC. Approval was based upon results from a single controlled trial, in which 74 patients with liver-isolated CRC metastases were randomly assigned to HIA chemotherapy with FUDR alone or in conjunction with a single intrahepatic artery administration of SIR-Spheres [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/99\">",
"     99",
"    </a>",
"    ]. Combined therapy was associated with a significantly better objective complete response rate (44 versus 18 percent), and median time to progression (16 versus 10 months), and similar grade 3 and 4 toxicity. Although the one, two, three, and five-year survival rates for patients receiving SIR-Spheres (72, 39, 17, and 4 percent, respectively) did not differ significantly from those of patients in the control arm (68, 29, 7, and 0 percent, respectively), Cox regression analysis suggested a survival benefit for patients who lived longer than 15 months.",
"   </p>",
"   <p>",
"    Two other randomized trials have compared SIR-Spheres versus intravenous chemotherapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small randomized phase II trial (n = 21) directly compared first-line IV",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      alone or preceded by a single injection of SIR-Spheres [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/100\">",
"       100",
"      </a>",
"      ]. Objective response rates (50 versus 0 percent), time to disease progression, and median survival (29 versus 13 months) were all significantly longer in the group receiving SIR-Spheres.",
"     </li>",
"     <li>",
"      More recently, a phase III trial directly compared first-line infusional 5-FU alone or preceded by a single injection of SIR-Spheres in 46 patients with liver-isolated metastatic colorectal cancer not amenable to curative surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/101\">",
"       101",
"      </a>",
"      ]. Radioembolization was well tolerated in conjunction with infusional 5-FU, and it significantly improved time to liver progression (5.5 versus 2.1 months). Although there was no significant difference in objective response rate (10 versus 0 percent), there was a significant different in overall disease control rate (partial response plus stable disease, 86 versus 35 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data are difficult to interpret due to the small size of the trials, the lower than expected response rates in the control groups, and the fact that modern therapeutic approaches to treatment of unresectable liver-isolated metastatic disease (cytotoxic chemotherapy using an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimen) were not used. SIR-Spheres&reg; is complex to administer, requiring two angiograms, a nuclear medicine study, and a significant amount of coordination among oncologists, nuclear medicine physicians, and interventional radiologists.",
"   </p>",
"   <p>",
"    Y90 radioembolization may be of greater utility when added to modern systemic chemotherapy, but the efficacy of combined therapy and the potential for additive toxicity is just beginning to be studied [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/102-105\">",
"     102-105",
"    </a>",
"    ]. A randomized trial, the SIRFLOX study to compare first-line treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short term infusional FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with and without SIR-Spheres is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of SIR-Spheres in patients who have failed multiple chemotherapy regimens is also just beginning to be explored [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/107-112\">",
"     107-112",
"    </a>",
"    ]. The largest series included 208 patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -refractory colorectal cancer liver metastases who were treated at seven different institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/108\">",
"     108",
"    </a>",
"    ]. The CT-defined partial response rate was 35 percent, and 70 percent had a serologic response (reduction in carcinoembryonic antigen). However, the wide range of delivered radioactivity, different treatment volume (ie, lobar versus whole liver), and",
"    <span class=\"nowrap\">",
"     method/timing",
"    </span>",
"    of posttreatment evaluation compromise the ability to interpret the results. Although there were some defined radiographic responses, the majority of patients died with persistent liver disease and uncontrolled systemic metastases.",
"   </p>",
"   <p>",
"    There are only limited data on the hepatic parenchymal response to radioembolization. Among the changes that are described are transient transaminase elevation and hyperbilirubinemia, ipsilateral hepatic lobar volume decrease with contralateral lobar hypertrophy (a phenomenon that has been termed \"radiation lobectomy\"), induction of liver fibrosis, and portal hypertension. The frequency and risk factors for development of these adverse effects, and their influence on liver insufficiency are not well characterized. Complications of radioembolization are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=see_link&amp;anchor=H441997277#H441997277\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of all of these issues, and the extraordinary expense of this therapy, it is difficult to know how to incorporate SIR-Spheres&reg; into the treatment scheme for patients with hepatic metastases from CRC. A consensus panel from the Radioembolization Brachytherapy Oncology Consortium suggested that radioembolization be limited to patients who meet the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/36/28234/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresectable metastatic hepatic disease with liver-dominant tumor burden, and a life expectancy &gt;3 months.",
"     </li>",
"     <li>",
"      An absolute contraindication to Y90 microsphere treatment is a pretreatment 99mTc macroaggregated albumin scan that demonstrates the potential for &ge;30 Gy radiation exposure to the lung or flow to the gastrointestinal tract that cannot be corrected by catheter techniques.",
"     </li>",
"     <li>",
"      Relative contraindications include limited hepatic reserve, irreversibly elevated serum bilirubin levels, compromised portal vein (unless selective or superselective radioembolization can be performed), and prior radiation therapy involving the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=see_link\">",
"       \"Patient information: Colon and rectal cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=see_link\">",
"       \"Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with isolated liver metastases from colorectal cancer who are not amenable to potentially curative resection because of tumor size, location, multifocality, or inadequate hepatic reserve, regional (liver-directed) treatment provides an alternative to systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who could be considered surgical candidates if their metastases were smaller, we suggest initial systemic chemotherapy followed by reevaluation for surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a limited number or metastases who are felt to be unable to tolerate surgery, we suggest regional tumor ablation rather than initial systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the decision is made to perform tumor ablation, we recommend radiofrequency ablation (RFA) as the procedure of choice (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The best results with RFA are in patients with three or fewer lesions, 5 cm or less in diameter, that are not located near major vascular structures. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Radiofrequency ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The regional administration of chemotherapy for intrahepatic metastases is based upon sound pharmacological principles and appears to increase the activity of 5-FU-based chemotherapy. The toxicity and complications of the intraarterial approach have been reduced with newer treatment regimens and greater experience with this treatment modality.",
"      <br/>",
"      <br/>",
"      Despite these technical advances and a multitude of trials, the relative benefit of hepatic intraarterial chemotherapy for patients with hepatic metastases from CRC remains unclear, particularly when compared to the efficacy of newer systemic chemotherapy regimens. If it is used, this approach should be restricted to centers with expertise in the technical aspects of regional chemotherapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hepatic intraarterial chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The place of radioembolization in the therapeutic armamentarium, particularly its utility in patients treated with modern combination chemotherapy, is unclear, and we suggest that it not be used (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Radioembolization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/2\">",
"      Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/3\">",
"      Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/4\">",
"      Steele G Jr, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991; 9:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/5\">",
"      Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996; 131:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/6\">",
"      Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran&ccedil;aise de Chirurgie. Cancer 1996; 77:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/7\">",
"      Yoon SS, Tanabe KK. Multidisciplinary management of metastatic colorectal cancer. Surg Oncol 1998; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/8\">",
"      Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/9\">",
"      Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/10\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Handbook for Reporting Results of Cancer Treatment, World Health Organization (Ed), WHO Offset Publication No. 48, Geneva, Switzerland 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/12\">",
"      Preketes AP, King J, Caplehorn JR, et al. CEA reduction after cryotherapy for liver metastases from colon cancer predicts survival. Aust N Z J Surg 1994; 64:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/13\">",
"      Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009; 45:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/14\">",
"      Amersi FF, McElrath-Garza A, Ahmad A, et al. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg 2006; 141:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/15\">",
"      Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002; 132:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/16\">",
"      Hildebrand P, Kleemann M, Roblick UJ, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg 2006; 391:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/17\">",
"      Hildebrand P, Leibecke T, Kleemann M, et al. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. Eur J Surg Oncol 2006; 32:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/18\">",
"      Ahmad A, Chen SL, Kavanagh MA, et al. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg 2006; 72:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/19\">",
"      Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/20\">",
"      Goldberg SN, Hahn PF, Tanabe KK, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 1998; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/21\">",
"      Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003; 14:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/22\">",
"      Machi J, Uchida S, Sumida K, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001; 5:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/23\">",
"      Head HW, Dodd GD 3rd, Dalrymple NC, et al. Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm: frequency of diaphragmatic injury. Radiology 2007; 243:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/24\">",
"      Tanabe KK, Curley SA, Dodd GD, et al. Radiofrequency ablation: the experts weigh in. Cancer 2004; 100:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/25\">",
"      Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol 2004; 5:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/26\">",
"      Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999; 230:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/27\">",
"      Machi J, Oishi AJ, Sumida K, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/28\">",
"      Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/29\">",
"      Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/30\">",
"      Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/31\">",
"      Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/32\">",
"      Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/33\">",
"      Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/34\">",
"      Otto G, D&uuml;ber C, Hoppe-Lotichius M, et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010; 251:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/35\">",
"      White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007; 11:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/36\">",
"      Lee WS, Yun SH, Chun HK, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008; 42:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/37\">",
"      Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008; 143:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/38\">",
"      Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 2012; 6:CD006317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/39\">",
"      Kornprat P, Jarnagin WR, DeMatteo RP, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 2007; 142:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/40\">",
"      Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/41\">",
"      Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005; 90:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/42\">",
"      Pawlik TM, Izzo F, Cohen DS, et al. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/43\">",
"      de Ba&egrave;re T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003; 181:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/44\">",
"      Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/45\">",
"      Liang P, Dong B, Yu X, et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. AJR Am J Roentgenol 2003; 181:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/46\">",
"      Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/47\">",
"      Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 2009; 251:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/48\">",
"      Muralidharan V, Christophi C. Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 2001; 76:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/49\">",
"      Pech M, Wieners G, Freund T, et al. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur J Med Res 2007; 12:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/50\">",
"      Christophi C, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. World J Surg 2004; 28:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/51\">",
"      Vogl TJ, Straub R, Eichler K, et al. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. Radiology 2004; 230:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/52\">",
"      Giorgio A, Tarantino L, Mariniello N, et al. [Ultrasonography-guided percutaneous ethanol injection in large an/or multiple liver metastasis]. Radiol Med 1998; 96:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/53\">",
"      Giovannini M, Seitz JF. Ultrasound-guided percutaneous alcohol injection of small liver metastases. Results in 40 patients. Cancer 1994; 73:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/54\">",
"      Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin Oncol 2005; 32:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/55\">",
"      Amin Z, Bown SG, Lees WR. Local treatment of colorectal liver metastases: a comparison of interstitial laser photocoagulation (ILP) and percutaneous alcohol injection (PAI). Clin Radiol 1993; 48:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/56\">",
"      BREEDIS C, YOUNG G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/57\">",
"      Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/58\">",
"      Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006; 26:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/59\">",
"      Poggi G, Quaretti P, Minoia C, et al. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 2008; 28:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/60\">",
"      Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/61\">",
"      Albert M, Kiefer MV, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/62\">",
"      Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/63\">",
"      Sanz-Altamira PM, Spence LD, Huberman MS, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 1997; 40:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/64\">",
"      Bavisotto LM, Patel NH, Althaus SJ, et al. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 1999; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/65\">",
"      Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/66\">",
"      Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/67\">",
"      Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/68\">",
"      Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/69\">",
"      Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/70\">",
"      Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/71\">",
"      Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/72\">",
"      Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/73\">",
"      Stagg RJ, Venook AP, Chase JL, et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/74\">",
"      Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. J Clin Oncol 1985; 3:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/75\">",
"      Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993; 114:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/76\">",
"      Ziessman HA, Thrall JH, Yang PJ, et al. Hepatic arterial perfusion scintigraphy with Tc-99m-MAA. Use of a totally implanted drug delivery system. Radiology 1984; 152:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/77\">",
"      Kemeny N, Niedzwiecki D, Shurgot B, Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 1989; 63:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/78\">",
"      Frye JW, Venook AP, Ostroff JW, et al. Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump. Gastrointest Endosc 1992; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/79\">",
"      Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/80\">",
"      Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/81\">",
"      Kemeny N, Seiter K, Conti JA, et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 1994; 73:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/82\">",
"      Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/83\">",
"      Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23:4881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/84\">",
"      Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/85\">",
"      Fiorentini G, Rossi S, Dentico P, et al. Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003; 89:382.",
"     </a>",
"    </li>",
"    <li>",
"     Bouchahda M, Tanaka K, Adam R, et al. Three-drug chronotherapy via hepatic artery for patients with liver-only metastases from colorectal cancer (abstract). J Clin Oncol 2005; 23:275s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/87\">",
"      Safi F, Bittner R, Roscher R, et al. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 1989; 64:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/88\">",
"      Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/89\">",
"      de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/90\">",
"      Lorenz M, M&uuml;ller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/91\">",
"      Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/92\">",
"      Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25:5649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/93\">",
"      Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23:8739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/94\">",
"      Topkan E, Onal HC, Yavuz MN. Managing liver metastases with conformal radiation therapy. J Support Oncol 2008; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/95\">",
"      Nag S, DeHaan M, Scruggs G, et al. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2006; 64:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/96\">",
"      Armstrong JG, Anderson LL, Harrison LB. Treatment of liver metastases from colorectal cancer with radioactive implants. Cancer 1994; 73:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/97\">",
"      Martinez-Monge R, Nag S, Nieroda CA, Martin EW. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver. Cancer 1999; 85:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/98\">",
"      Donath D, Nori D, Turnbull A, et al. Brachytherapy in the treatment of solitary colorectal metastases to the liver. J Surg Oncol 1990; 44:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/99\">",
"      Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/100\">",
"      Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/101\">",
"      Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28:3687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/102\">",
"      Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/103\">",
"      Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/104\">",
"      Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/105\">",
"      van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009; 27:4089.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trial information available online at file://clinicaltrials.gov/ct2/show/NCT00724503 (Accessed on May 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/107\">",
"      Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005; 16:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/108\">",
"      Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/109\">",
"      Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/110\">",
"      Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology 2008; 247:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/111\">",
"      Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/112\">",
"      Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/36/28234/abstract/113\">",
"      Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2515 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-D3B5B19E3F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28234=[""].join("\n");
var outline_f27_36_28234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOPSY CONFIRMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TUMOR ABLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assessing clinical benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperthermic coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Microwave hyperthermia and interstitial laser ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25786933\">",
"      Percutaneous ethanol or acetic acid injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary: Local ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEPATIC INTRAARTERIAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3152022\">",
"      Transarterial chemoembolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3152043\">",
"      HIA chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Early phase III trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Technique and complications of HIA pump placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Optimizing chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25787209\">",
"      5-FU-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25787224\">",
"      Oxaliplatin and irinotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25787231\">",
"      HIA plus systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Contemporary randomized trials and meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stereotactic radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24524\" title=\"table 1\">",
"      Hepatic resection for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/0/6148?source=related_link\">",
"      Patient information: Colon and rectal cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/27/19890?source=related_link\">",
"      Patient information: Colon and rectal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/22/40293?source=related_link\">",
"      Patient information: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_36_28235="Diagnostic criteria NF2";
var content_f27_36_28235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for NF2 (these include the NIH criteria with additional criteria)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Bilateral vestibular schwannomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A first-degree relative with NF2",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Unilateral vestibular schwannoma",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Any two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral vestibular schwannoma",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Any two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple meningiomas",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Unilateral vestibular schwannoma",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Any two of: schwannoma, glioma, neurofibroma, cataract",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * \"Any two of\" = two individual tumors or cataract.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Evans DG. Neurofibromatosis 2 (Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II). Genet Med 2009; 11:599. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28235=[""].join("\n");
var outline_f27_36_28235=null;
var title_f27_36_28236="Glenohumeral joint movements";
var content_f27_36_28236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glenohumeral joint movements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Movement (function)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prime mover(s) (from pendent position)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Synergists",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexion",
"       </td>",
"       <td>",
"        Pectoralis major (clavicular head); deltoid (anterior part)",
"       </td>",
"       <td>",
"        Coracobrachialis (assisted by biceps)",
"       </td>",
"       <td>",
"        From fully extended position to its own (coronal) plane, sternocostal head of pectoralis major is major force",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extension",
"       </td>",
"       <td>",
"        Deltoid (posterior part)",
"       </td>",
"       <td>",
"        Teres major",
"       </td>",
"       <td>",
"        Latissimus dorsi, sternocostal head of pectoralis major, and long head of triceps act from fully flexed position to their own (coronal) planes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abduction",
"       </td>",
"       <td>",
"        Deltoid (as a whole, but especially central part)",
"       </td>",
"       <td>",
"        Supraspinatus",
"       </td>",
"       <td>",
"        Supraspinatus is particularly important in initiating movement; also, upward rotation of scapula occurs throughout movement, making a significant contribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adduction",
"       </td>",
"       <td>",
"        Pectoralis major; latissimus dorsi",
"       </td>",
"       <td>",
"        Subscapularis; infraspinatus: teres minor",
"       </td>",
"       <td>",
"        In upright position and in absence of resistance, gravity is prime mover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal&nbsp;rotation",
"       </td>",
"       <td>",
"        Subscapularis",
"       </td>",
"       <td>",
"        Pectoralis major; deltoid (anterior fibers); latissimus dorsi",
"       </td>",
"       <td rowspan=\"2\">",
"        With arm elevated, \"synergists\" become more important than prime movers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        External&nbsp;rotation",
"       </td>",
"       <td>",
"        Infraspinatus",
"       </td>",
"       <td>",
"        Teres minor; deltoid (posterior fibers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tensors of articular capsule (to hold head of humerus against glenoid cavity)",
"       </td>",
"       <td>",
"        Supscapularis; infraspinatus (simultaneously)",
"       </td>",
"       <td>",
"        Supraspinatus; teres minor",
"       </td>",
"       <td>",
"        Rotator cuff (SITS) muscles acting together; when \"resting\", their tonus adequately maintains integrity of joint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resisting downward dislocation (shunt muscles)",
"       </td>",
"       <td>",
"        Deltoid (as a whole)",
"       </td>",
"       <td>",
"        Long head of triceps: coracobrachialis; short head of biceps",
"       </td>",
"       <td>",
"        Used especially when carrying heavy objects (suitcases, buckets)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28236=[""].join("\n");
var outline_f27_36_28236=null;
var title_f27_36_28237="Perfusion imaging in ER";
var content_f27_36_28237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Resting SPECT imaging in evaluation of chest pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 216px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a group of 357 patients presenting to the emergency room, 20 had a documented myocardial infarction (MI). Resting perfusion imaging with technetium-99m tetrofosmin had a sensitivity of 90 percent but a positive predictive value of only 12 percent since most positive tests were false positives. However, a negative study was associated with a very low cardiac event rate (negative PV 99 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Heller GV, Stowers SA, Hendel RA. J Am Coll Cardiol 1998; 31:1011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28237=[""].join("\n");
var outline_f27_36_28237=null;
var title_f27_36_28238="Promotion of general knowledge";
var content_f27_36_28238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70285%7EPEDS%2F74888%7EPEDS%2F54909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70285%7EPEDS%2F74888%7EPEDS%2F54909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggestions for enhancing a child's cognitive and general knowledge skills before kindergarten entry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parents can promote cognitive",
"skills by asking their children to place information or objects* into",
"categories according to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kind",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parents can enhance",
"their child's arithmetic skills by teaching them to:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Count by rote to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Understand number concepts to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehend the concept of 'each'",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify a circle, triangle, and square",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Comprehend the concepts of",
"'more than, less than, same'",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        \"Identify which group has",
"more/less/the",
"same amount\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parents can help to",
"increase their children's knowledge of general, musical, artistic,",
"scientific, historical, and literary information by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visiting museums, exhibits, zoos, and dramatic theatre",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Listening to audio-books-on-tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viewing videos, television, and",
"illustrated books with their child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discussing what they see or hear as",
"they take walks or drive along roadways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The following",
"instructional experiences may be beneficial in helping children learn",
"to explain information precisely, respond to questions completely, and",
"increase attention to details:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Describe the attributes and",
"functions of a familiar object or objects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respond to specific questions",
"related to the name, color, size, use, etc of the object",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Respond to the",
"following questions related to situations, pictures of familiar",
"objects:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        What can you tell me about this?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        What else can you tell me",
"about it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        What more can you think of to",
"tell me about it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Are there any",
"other things about it that are important?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Eg, toys, laundry, groceries, etc.&nbsp;",
"    </div>",
"    <div class=\"reference\">",
"     Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggestions for enhancing a child's language and literacy skills before kindergarten entry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parents are encouraged to provide repeated experiences in development of the following areas:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Expressive and receptive language readiness skills:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Understand and express the following linguistic concepts:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Quality: Show me the one that is the same. Show me the one that is different.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Quantity: Which coat has more/fewer/the most buttons?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       Position words:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Put the book on the lower shelf.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Show me the boy farthest from the tree.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Show me the boy nearest to the tree.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       (Other positions are in front of, behind, ahead of, first, last, etc.)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Direction words: Take the doll up the ladder. Take the doll down the ladder.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Time words: Before I clap my hands, stand up.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Verb tense, passive: Show me: The truck was hit by the car.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Identify the sound patterns of words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rhyming words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rhyming sentences",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nursery rhymes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       Alliteration: Sister Suzie is sitting by the seashore sifting sand...",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       What is the common sound?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Understand and re-tell narrative stories",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Reading readiness skills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Recognize the meaning of common signs and symbols in the environment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sing the ABC song",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Develop an awareness of print",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me the title.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me where I should begin reading.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       What story do the pictures tell?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me where the story ends.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me how to turn the pages.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Writing readiness skills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hold a pencil or crayon with an appropriate grasp",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Assemble multi-piece wooden and cardboard puzzles of people, animals, forms, numbers, or letters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Create models of airplanes, prehistoric animals, cars, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Use crayons or a pencil to draw, follow the dots, or solve maze tasks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Copy patterns using beads on a string, a pegboard, or parquetry blocks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Use wooden or plastic blocks to match geometric shapes and build copies of models",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Find shapes or designs in a picture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Copy geometric configurations with rubber bands stretched between rows of nails on a board",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggestions for enhancing a child's psychosocial skills before kindergarten entry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parents can promote psychosocial skill development in their children by:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Modeling and encouraging the use of descriptive words to express feelings, rather than physical reactions. Label both positive and negative emotions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Practicing taking turns whenever possible (eg, in turning pages of a book being read to them, in describing what was seen or what activities were experienced on a family outing, when choosing games to play, etc).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Talking to the child about social interactions witnessed in public or on television, noting what behaviors led to problems, what behaviors were helpful, how a situation might have ended differently if one behavior had been changed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Practicing listening and following simple directions (eg, \"put the ball behind the chair then take the book to the table, then sit down on the rug\"). Start with a single direction, then two-step directions, then three-step directions, etc., as the child demonstrates mastery.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reinforcing the child for sharing belongings with other individuals, taking turns, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Practicing sitting and working quietly at a table for a few moments, and gradually increasing the amount of time spent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parents can increase their child's exposure to peers and help them to make lasting friendships by:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Joining non-competitive extracurricular activities such as scouting groups (Girl Scouts, Boy Scouts, Indian Princesses, Indian Guides) or activities/sports offered through local organizations, such as the YMCA or museums.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inviting friends or neighborhood children to go on family outings to the park, movies, shopping, out to eat, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inviting playmates over to the house on evenings and weekends where parents can monitor and model appropriate social skills and problem solving and to intervene if problems arise.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28238=[""].join("\n");
var outline_f27_36_28238=null;
var title_f27_36_28239="Estimated TB incidence and prevalence by country";
var content_f27_36_28239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated epidemiological burden of TB, 2009*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Mortality",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Prevalence",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        HIV prevalence in incident TB cases (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Best",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Low",
"       </td>",
"       <td class=\"subtitle2\">",
"        High",
"       </td>",
"       <td class=\"subtitle2\">",
"        Best",
"       </td>",
"       <td class=\"subtitle2\">",
"        Low",
"       </td>",
"       <td class=\"subtitle2\">",
"        High",
"       </td>",
"       <td class=\"subtitle2\">",
"        Best",
"       </td>",
"       <td class=\"subtitle2\">",
"        Low",
"       </td>",
"       <td class=\"subtitle2\">",
"        High",
"       </td>",
"       <td class=\"subtitle2\">",
"        Best",
"       </td>",
"       <td class=\"subtitle2\">",
"        Low",
"       </td>",
"       <td class=\"subtitle2\">",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Afghanistan",
"       </td>",
"       <td>",
"        28,150",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        --",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        --",
"       </td>",
"       <td>",
"        --",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bangladesh",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        162,221",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        690",
"       </td>",
"       <td>",
"        320",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        360",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        440",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brazil",
"       </td>",
"       <td>",
"        193,734",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cambodia",
"       </td>",
"       <td>",
"        14,805",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        China",
"       </td>",
"       <td>",
"        1,345,751",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        740",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        1500",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DR Congo",
"       </td>",
"       <td>",
"        66,020",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        430",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        690",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethiopia",
"       </td>",
"       <td>",
"        82,825",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        480",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        790",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        360",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        India",
"       </td>",
"       <td>",
"        1,198,003",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        430",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        1300",
"       </td>",
"       <td>",
"        5000",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        2400",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indonesia",
"       </td>",
"       <td>",
"        229,965",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        660",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        430",
"       </td>",
"       <td>",
"        350",
"       </td>",
"       <td>",
"        520",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kenya",
"       </td>",
"       <td>",
"        39,802",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mozambique",
"       </td>",
"       <td>",
"        22,894",
"       </td>",
"       <td>",
"        8.8",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myanmar",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        50,020",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        490",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nigeria",
"       </td>",
"       <td>",
"        154,729",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        830",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        1400",
"       </td>",
"       <td>",
"        460",
"       </td>",
"       <td>",
"        370",
"       </td>",
"       <td>",
"        550",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pakistan",
"       </td>",
"       <td>",
"        180,808",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        640",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        420",
"       </td>",
"       <td>",
"        340",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Philippines",
"       </td>",
"       <td>",
"        91,983",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        480",
"       </td>",
"       <td>",
"        450",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        310",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Russian Federation",
"       </td>",
"       <td>",
"        140,874",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        320",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        South Africa",
"       </td>",
"       <td>",
"        50,110",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        390",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        650",
"       </td>",
"       <td>",
"        490",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        590",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thailand",
"       </td>",
"       <td>",
"        67,764",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uganda",
"       </td>",
"       <td>",
"        32,710",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        UR Tanzania",
"       </td>",
"       <td>",
"        43,739",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        9. 2",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viet Nam",
"       </td>",
"       <td>",
"        88,069",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zimbabwe",
"       </td>",
"       <td>",
"        12,523",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         High-burden countries",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         4,297,498",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1100",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         930",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1200",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11,000",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8900",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14,000",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7600",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         7100",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8100",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         13",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Numbers in thousands except where indicated.",
"    <div class=\"footnotes\">",
"     * Numbers for mortality, prevalence, and incidence shown to two significant figures. Totals for HBCs and globally computed prior to rounding using Monte Carlo simulations.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10.",
"      <br>",
"       &Delta; Best, low, and high indicate best estimates followed by lower and upper bounds. The lower and upper bounds are defined as the 2.5",
"       <sup>",
"        th",
"       </sup>",
"       and 97.5",
"       <sup>",
"        th",
"       </sup>",
"       centiles of outcome distributions produced in simulations.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Indicates no data reported.",
"        <br>",
"         &sect; Bangladesh completed a survey of the prevalence of TB disease in 2009. A reassessment of the epidemiological burden of TB, using data from the survey combined with an in-depth analysis of surveillance and programmatic data, is being undertaken in 2011.",
"         <br>",
"          &yen; Myanmar completed a survey of the prevalence of TB disease in 2010. A reassessment of the epidemiological burden of TB will be undertaken following finalization and dissemination of survey results.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. WHO Report 2010: Global Tuberculosis Control. WHO/HTM/TB/2010.7. Geneva, 2010. Copyright &copy; 2010 WHO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_36_28239=[""].join("\n");
var outline_f27_36_28239=null;
